Races of small molecule clinical trials for the treatment of COVID-19: An up-to-date comprehensive review

Suwen Hu1,2,3,4,5,6 | Songwei Jiang1,2,3,4 | Xiang Qi1,2,3,4 | Renren Bai1,2,3,4 | Xiang-Yang Ye Ph.D., Professor1,2,3,4 | Tian Xie1,2,3,4

1School of Pharmacy, Hangzhou Normal University, Hangzhou, China
2Key Laboratory of Element Class Anti-Cancer Chinese Medicine of Zhejiang Province, Hangzhou Normal University, Hangzhou, China
3Engineering Laboratory of Development and Application of Traditional Chinese Medicine from Zhejiang Province, Hangzhou Normal University, Hangzhou, China
4Collaborative Innovation Center of Chinese Medicines from Zhejiang Province, Hangzhou Normal University, Hangzhou, China
5Hangzhou Huadong Medicine Group, Pharmaceutical Research Institute Co. Ltd., Hangzhou, China
6Department of Chemistry and Biochemistry Los Angeles, University of California, Los Angeles, California, USA

Correspondence
Xiang-Yang Ye, Tian Xie and Renren Bai, School of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China.
Email: xyye@hznzu.edu.cn, xbs@hznzu.edu.cn and renrenbai@hznzu.edu.cn

Funding information
Hangzhou “115” overseas intelligence program, Grant/Award Number: 2020C001; Hangzhou Normal University startup fund, Grant/Award Number: 4125C021920419; Hangzhou Normal University, School of Medicine Teaching Reform Fund, Grant/Award Number: 412553010012; National Natural Science Foundation of China, Grant/Award Numbers: 81730108, 81803340, 81973635, 82073686

Abstract
The coronavirus disease-19 (COVID-19) pandemic has become a global threat since its first outbreak at the end of 2019. Several review articles have been published recently, focusing on the aspects of target biology, drug repurposing, and mechanisms of action (MOAs) for potential treatment. This review gathers all small molecules currently in active clinical trials, categorizes them into six sub-classes, and summarizes their clinical progress. The aim is to provide the researchers from both pharmaceutical industries and academic institutes with the handful information and dataset to accelerate their research programs in searching effective small molecule therapy for treatment of COVID-19.

KEYWORDS
anti-viral agent, COVID-19, small molecules

Abbreviations: 3CLpro, 3C-like protease; ACE, angiotensin-converting enzyme; ACE2, angiotensin-converting enzyme 2; ALDH1, aldehyde dehydrogenase 1; Ang II, angiotensin II; AR, androgen receptor; ARDS, acute respiratory distress syndrome; AT, angiotensin II receptor type; AT1R, angiotensin receptor type I; ATF-6, activating transcription factor 6; ATP, adenosine triphosphate; BTK, Bruton’s tyrosine kinase; CCL2, C-C Motif Chemokine Ligand 2; CCR2, C-C chemokine receptor type 2; CCR5, C-C chemokine receptor type 5; CD11b, cluster of differentiation molecule 11b; CD147, cluster of differentiation 147; CD16, cluster of differentiation 16; CD18, integrin beta chain-2; CD4, cluster of differentiation 4; CD62L, L-selectin; COX, cyclooxygenase; COVID-19, coronavirus disease 2019; CRP, C reactive protein; CVD, cardiovascular disease; COVID-19, coronavirus disease 2019; COX-1, cyclooxygenase-1; COX-2, cyclooxygenase-2; CRS, cytokine release syndrome; CSS, cytokine storm syndrome; CUL4A/BRX1-DBD1, cullin 4- ring box protein- DNA binding protein 1; CYP3A4, cytochrome P450 3A4; cyclo, cyclosporine; DPP4, dipeptidyl peptidase-4; EGFR, epidermal growth factor receptor; FDA, food and drug administration; GLP-1, glucagon-like peptide-1; G-CSF, granulocyte colony-stimulating factor; HCoV-229E, human coronavirus 229E; HCoV-HKU1, human coronavirus HKU1; HCoV-NL63, human coronavirus NL63; HCoV-OC43, human coronavirus OC43; HCV, hepatitis C virus; hERG, the human Ether-à-go-go-Related Gene; HIV, human immunodeficiency viruses; HMG-CoA, β-Hydroxy-β-methylglutaryl-CoA; HSV, herpes simplex virus; IFL, Interleukin; IMPDH, Inosine-5'-monophosphate dehydrogenase; JAK–STAT, Janus kinase-signal transducer and activator of transcription protein; MAPK, mitogen-activated protein kinase; MAS1, mas-related G-protein coupled receptor; Mas, mas receptor; MCL, monoclonal antibody protein-1; MERS-CoV, middle East respiratory syndrome-related coronavirus; MOA, mechanism of action; MPTP, main protease; mRNA, messenger ribonucleic acid; MRSA, methicillin-resistant Staphylococcus aureus; mTOR, mechanistic target of rapamycin; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cell; NIH, National Institutes of Health; NK-1, neuropeptide; NLR, NLR family pyrin domain containing; NS3A, NS5A, non-structural protein 3A, non-structural protein 5A; NS5A, non-structural protein 5A; NSCLC, non-small-cell lung carcinoma; NSP15, nonstructural protein 15; PARP, poly(ADP-ribose) polymerase; P-EE, P-epididymal; P-EP, P-epithelial; P-gp, P-glycoprotein; P2K, phosphatidylinositol 3-kinase; PTSD, post-traumatic stress disorder; RAR, retinoic acid receptor; Ras, ras protein; RAS, ras family; Ras, ras related; R-associated G-protein-complex associated; RAS-E, Ras-activated; RAS-E1, Ras-activated; RAS-M, Ras-monomeric; RAS-P, Ras-polymorphic; RAS-R, Ras-ribosomal; RD, ribosomal; RNA, ribonucleic acid; ROS, reactive oxygen species; S1P1, sphingosine-1-phosphate receptor 1; SARS-CoV-1, severe acute respiratory syndrome coronavirus; SARS-CoV-2, severe Acute Respiratory Syndrome Coronavirus 2; SGLT2, sodium/glucose cotransporter 2; SV-SMC, saphenous vein- structural maintenance of chromosomes protein; TLR, toll-like receptor; TNF, tumor necrosis factor; TCR, T-cell receptor; VDCC, voltage-dependent calcium channel; vRNP, viral ribonucleoprotein; WHO, world health organization; XPO1, exportin 1.
Since its first large-scale outbreak in central China in December 2019, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the coronavirus disease-19 (COVID-19) pandemic globally (Sahin et al., 2020; Wang, Hu, et al., 2020), and has led to severe damage to human lives and the economy of more than 200 countries worldwide. By the time this manuscript is submitted, 143,445,675 people have been infected by this virus, and the death toll mounts up to 3,051,736 globally (World Health Organization website, n.d.).

Besides SARS-CoV-2, six more coronaviruses have been characterized by now: human CoV229E (HCoV-229E, 1966), human CoV OC43 (HCoV-OC43, 1967), human CoV HKU1 (HCoV-HKU1, 2004), human CoV NL63 (HCoV-NL63, 2004), severe acute respiratory syndrome CoV (SARS-CoV, 2003), and Middle East respiratory syndrome CoV (MERS-CoV, 2013). Chronological analysis of the commence time and severity of these viruses suggests that the outbreak cycle of the coronaviruses is getting shorter and shorter, and the impact of the viruses is getting worse and worse. To treat current SARS-CoV-2 infection, and more importantly to prepare for unforeseeable new coronaviruses in the future, scientists from the globe respond quickly in attempt to identify suitable solutions such as small molecules for the potential therapy or vaccines for the prevention.

SARS-CoV-2 belongs to a class of coronaviruses featured with positive-sense, enveloped, single-stranded RNA (Zeidler & Karpinski, 2020). The spike proteins (S proteins) on the viral envelope include two subunits, S1 and S2, which are the key surface proteins that participate in the interaction between the viruses and the host cells, and eventually promote the virus to enter the host cell (Walls et al., 2020). SARS-CoV-2 uses angiotensin-converting enzyme 2 (ACE2) receptors to enter the lung cells (Figure 1a). After the attachment of the virus to the host cells, the S protein of the virus interacts with protease enzymes from the host cells, enabling the virus fusing to the host cell membrane (Cascella et al., 2021). This process relies on transmembrane serine protease (TMPRSS2) activating S proteins (Hoffmann et al., 2020; Valencia, 2020). After the genomic RNA released into the cytoplasm and then translated to produce polyproteins, which is facilitated by virally encoded chymotrypsin-like protease (3C-like) or main protease (M) (Cascella et al., 2021). Polyproteins cleavage affords non-structural proteins for the viral RNA replicase-transcriptase complex. Viral nucleocapsids are assembled with the structural proteins after the viral replication and transcription. Upon encasing viral RNA, these nucleocapsids form the new virions and are then released from the cells via exocytosis (Valencia, 2020). Clinical studies indicate that several cytokines from severe patients’ tissue undergo extensive changes, which play a crucial role in the COVID-19 pathogenesis (Liu, Zhang, Huang, Yang, et al., 2020; Mehta, McAuley, et al., 2020; Wan et al., 2020). Hypercytokinemia (also known as “cytokine storm”) may play as a pivotal role in life-threatening pathological processes (Figure 1b) (Xu, Shi, Li, & Zhou, 2020; Xu, Shi, Wang, et al., 2020). It has been proven that CD4+ T cells are rapidly activated to secret inflammatory cytokines upon the infection with SARS-CoV-2, which further lead to CD14+ monocyte activation with high interleukin expression (such as IL-1, IL-6 etc. see Figure 1b) (Zhou, Fu, et al., 2020). Thus, blocking the IL-1 or the IL-6 receptors could potentially alleviate...
immunopathology caused by SARS-CoV-2. The pulmonary renin-angiotensin system (RAS) is composed by two pathways, whose balance is crucial for pulmonary homeostasis (Figure 1c). Angiotensin II (Ang II), generated by endothelial ACE, acts on angiotensin II receptor type 1 (AT1) to promote pro-inflammatory effects and vasoconstriction, whereas epithelial ACE2 cleaves Ang II into Ang (1–7), which acts on the MAS1 (Mas proto-oncogene) oncogene to exert anti-inflammatory and vasodilatory effects. The ACE-dependent Ang II formation is a vital pathophysiological mechanism in different forms of acute respiratory distress syndrome (ARDS) (South et al., 2020).

SARS-CoV-2 interacts with ACE2, triggers ACE2 degradation and the ratio of ACE/ACE2 imbalance, further drives Ang II-mediated vascular inflammation and pulmonary injury which lead to severe COVID-19 symptoms (Figure 1c) (South et al., 2020).

Global scientific communities and pharmaceutical industries have been racing for success to cope with the COVID-19 pandemic in two major approaches: vaccines for the prevention (Buchholz et al., 2004; Cheng et al., 2020) and small molecule drugs for the potential treatment (Clinical trial ID: NCT04252885, n.d.; Cava et al., 2020; Kadam & Wilson, 2017; Lu, 2020; Pant et al., 2021; Sheahan, Sims, Leist, et al., 2020; Wu et al., 2020; Zhou, Hou, et al., 2020). The vaccine approach might ultimately be the most effective solution to the current pandemic but also could prepare for diseases caused by unforeseeable new coronaviruses in the future.

Since 2020, several review articles have been published regarding the advances of coronavirus treatment in different aspects. For example, Pillaiyar et al. (2020) reviewed the small molecule inhibitors for the potential treatment of coronavirus by focusing on the drug repurposing and drug discovery stage. Zhu et al. (2021), Zeng et al. (2020) used the deep learning approach to identify 41 old drugs potentially repurposable for treatment of COVID-19. Jean et al. (2020) reviewed the treatment reality and challenges for COVID-19. Zhang & Penninger et al. (2020) reviewed the ACE2 as a potential therapeutic target for COVID-19. Ghosh et al. (2020) summarized the drug development and medicinal chemistry aspect of COVID-19 therapeutics. Naujokat et al. (2020) concisely summarized the candidate drugs against COVID-19 by discussing some of the recent clinical studies, but not in a comprehensive manner. Monpara et al. (2020) focused on COVID-19 associated complications and biological targets for potential treatment. Most recently, Alahari et al. reviewed the mechanisms of action (MOAs) for repurposing drugs in the treatment of COVID-19 (Yousefi et al., 2021). In addition to above reviews, other approaches such as drug repurposing strategy (DRS) (Sahoo et al., 2021), system biology (Jaiswal et al., 2020), and computation practices (Ojha et al., 2021) were also reviewed recently.

Focusing on the small molecule approach, this article systematically summarizes those small molecules in current clinical trials for the potential treatment of COVID-19 in a comprehensive manner. By the time this review is submitted (April 22, 2021), there are 5441 COVID-19 related clinical studies listed on the NIH Clinical Trials website (http://ClinicalTrials.gov), ranging from evaluation of small molecule pharmacotherapies, mesenchymal stem cells or T-cell-based therapies, convalescent plasma therapies, and immunoglobulins to medical devices in the treatment of COVID-19. Most of the clinical studies are in Phases II–IV stages. Drug repurposing, defined as finding new indications for existing approved drugs (Tobinick, 2009), is of particular interest in the response to the COVID-19 pandemic emergency and urgency. Historic data suggest that de novo drug development typically takes 10 to 17 years and costs 800 million USD (Tobinick, 2009). Therefore, de novo drugs approach for combating COVID-19 might not turn out to be effective and satisfactory in the current pandemic emergency. On the other hand, the drug repurposing approach has been proven to be practical and successful in several cases. This approach significantly shortens the development time and reduces the cost. Repurposing existing drugs to treat COVID-19 is biologically feasible as SARS-CoV-2 shares some similarities with other coronaviruses, such as SARS-CoV and MERS-CoV (Chen, Tian, et al., 2020), and there are many successful precedents in repurposing antivirals for new virus targets (Mercorelli et al., 2018). Indeed, most of the drugs currently in clinical trials for COVID-19 are repurposed from approved antiviral drugs.

Data mining on more than four thousand clinical trials related to COVID-19 provided us with a pretty large dataset related to small molecules approach. To better discuss them, those small molecules were categorized into six classes based on the clinical features of COVID-19 and possible MOAs. The purpose of this review is to provide the researchers from both pharmaceutical industries and academic institutes with a comprehensive summary in this field so that to save their time in drug discovery research and to accelerate the finding of effective therapy for COVID-19.

2 | TYPES OF AGENTS IN CLINICAL TRAILS

To facilitate the interity of the review, we manually sorted out the drugs currently in clinical trials by querying the drug database from the FDA. Thus, for each identified small molecular drug, we searched for clinical trials on NIH Clinical Trials website using the name of drug plus “COVID-19” and screened thoroughly the results obtained. As of April 22, 2021, there are 126 small molecule drugs in at least 777 clinical trials with various stages for the potential treatment of COVID-19. These agents are classified into six categories based on their probable MOAs (Figures 2–4): (1) blocking virus-cell membrane fusion and entry (25 agents, accounting for 20%); (2) inhibiting viral replication (29 agents, accounting for 23%); (3) addressing cytokine storm syndrome (CSS) (51 agents, accounting for 40%); (4) modulating immune system (10 agents, accounting for 8%); (5) anticoagulant therapy (7 agents, accounting for 6%); and (6) antioxidant supplement (4 agents, accounting for 3%). On the other hand, all clinical candidates are grouped into four small subclasses based on their clinical stages. Thus, there are 4 agents in Phase I, 42 agents in Phase II, 46 agents in Phase III, and 34 agents in Phase IV (Figures 2–4).
2.1 | Blocking virus-cell membrane fusion and entry

Mounting studies suggest that SARS-CoV-2 invades into the membrane of the host cells mainly through the endocytosis after the S protein binding to ACE2 on the surface of the host cells (Yang & Shen, 2020). Then the S protein with the altered configuration facilitates the viral envelope to fuse with the host cell membrane via the endosome pathway. At present, agents such as bromhexine, camostat, arbidol, linagliptin, chlorpromazine, etc. are being tested to block endocytosis while hydroxychloroquine and chloroquine are being investigated to block the viral genome released into the cytoplasm. However, the data from clinical trials indicate that antimalarial drug hydroxychloroquine neither helps COVID-19 patients improve the recovery or reduce their symptoms nor prevents coronavirus infection in healthy people (Self et al., 2020). Both the World Health Organization (WHO) and NIH have suspended the clinical trials related to chloroquine class of medicines. The ongoing clinical trials of potential drugs targeting to block viral entry into the host cells are summarized in Table 1.

2.2 | Inhibiting the virus replication

There are two mainly targets inhibiting virus replication: (1) the protease (3CL\textsuperscript{pro} and PL\textsuperscript{pro}); and (2) the RNA-dependent RNA polymerase (RdRP). Anti-HIV agents (lopinavir or ritonavir) inhibit protease 3CL\textsuperscript{pro}, thereby blocking the formation of non-structural proteins. In July 2020, the WHO announced the suspension of the lopinavir/ritonavir combination clinical trial, citing little or no effect in reducing the death rate of hospitalized COVID-19 patients in the branch trial (News press from WHO website, 2021). PF-07321332 and PF-07304814 are potent and orally active SARS-CoV 3C-like protease (3CL\textsuperscript{pro}) inhibitors currently in multiple clinical trials including Phase
III (Vandyck & Deval, 2021). On the other hand, RdRP inhibitors such as remdesivir (Grein et al., 2020), sofosbuvir, and galidesivir could block the replication of the viral genome and the formation of structural proteins. Discovered by Gilead Sciences, remdesivir is the first drug to receive emergency FDA approval as sympathy medication for COVID-19 patients and is currently under various forms of approval in several countries. Specifically, molnupiravir (aka EIDD-2801 and MK-4482) induced RNA mutagenesis by the viral RNA-dependent RdRp. Molnupiravir showed an exciting experimental results in phase 2 clinical trials, and was one of the most promising small molecule anti-coronavirus drugs at present (Imran et al., 2021; Kabinger & Stiller, 2021; Malone & Campbell, 2021). In October 2021, Merck Co. submitted an Emergency Use Authorization (EUA) application to the US Food and Drug Administration (FDA) for molnupiravir based on the promising results from the Phase 3 MOVEOUT clinical trial (Press releas, Merck Company website, 2021). If approved, molnupiravir will be the first oral drug to treat COVID-19. Clinical trials for inhibiting virus replication are summarized in Table 2.

### 2.3 Addressing CSS

CSS refers to a group of related medical conditions in which the immune system releases excess of inflammatory signals (interferons,
| Drug name and structure | Original mechanism | FDA-approved indication(s)                                                                 | Possible mechanism for anti-COVID-19                                                                 | Clinical trials ID (stage)                                                                 | The highest anti-COVID-19 phase/ID/status/start-(estimated)end dates | References |
|-------------------------|--------------------|------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|---------------------------------------------------------------------|-------------|
| Ramipril                | ACE inhibitor      | Type 2 diabetes, vascular disease, hypertension, metabolic syndrome X, peripheral arterial disease, kidney transplant | ACE inhibitor                                                                                      | NCT04366050 (Phase 2)                                                                      | Phase 2/NCT04366050/enrolling by invitation/May 2020-May 2021       | (Amat-Santos et al., 2020)                                         |
| Atovaquone              | Mitochondrial cytochrome bcl complex inhibitor, antimalarial agent | HIV infections, malaria, plasmodium falciparum malaria, rabies | Elevating endosomal pH and interfere with ACE2 glycosylation                                      | NCT04339426 (Phase 2)  NCT04456153 (Phase 2)                                           | Phase 2/NCT04456153/completed/July 22, 2020-January 31, 2021       | (Clinical trial ID: NCT04456153, n.d.; Farag et al., 2020; Sachdeva et al., 2020) |
| Enzalutamide            | Androgen receptor (AR) antagonist | Prostate cancer | Blocking TMPRSS2                                                                                     | NCT04456049 (Phase 2)  NCT04475601 (Phase 2)                                           | Phase 2/NCT04475601/recruiting/July 15, 2020-July 8, 2021           | (Cattrini et al., 2020)                                           |
| Maraviroc               | CCR5 antagonist    | HIV infection, endothelial dysfunction, Inhibiting s-protein mediated cell fusion and SARS-CoV-2 multiplication | NCT04441385 (Phase 2)  NCT04475991 (Phase 2)  NCT04710199 (Phase 2)  NCT04435522 (Phase 1) | Phase 2/NCT04441385/recruiting/June 26, 2020-November 30, 2020 | (Koenig et al., 2020; Risner et al., 2020; Shamsi et al., 2020)     | |
| Losartan                | AT II receptor antagonist | Hypertension, kidney disease, proteinuria, emphysema, colitis, etc. | ACE2 blocker preventing virus entry into the host cells                                             | Approximately 8 clinical trials, some of the examples are: NCT04335123 (Phase 1)  NCT04447235 (Phase 2)  NCT04428268 (Phase 2)  NCT04643691 (Phase 2)  NCT04311177 (Phase 2)  NCT04312009 (Phase 2)  NCT04606563 (Phase 3)  NCT04343001 (Phase 3) | Phase 3/NCT04606563/recruiting/October 9, 2020-June 30, 2021 | (Gurwitz, 2020; Messerli et al., 2020)                              |
| Isotretinoin (13-cis-retinoic acid) | Anti-apoptosis | Severe acne | Down-regulates ACE2 receptors, combination with all-trans retinoic acid may enhances neutralizing antibodies in COVID-19 infected Patients | Approximately 9 clinical trials, some of the examples are: NCT04353180 (Phase 3)  NCT04396067 (Phase 2)  NCT04577378 (Phase 2)  NCT04389580 (Phase 2)  NCT04578236 (Phase 2)  NCT04361422 (Phase 3)  NCT04382950 (Phase 1) | Phase 3/NCT04353180/not yet recruiting/October 2020-June 2021 | (Hamouda Elgarhy, 2020)                                           |

(Continues)
| Drug name and structure | Original mechanism | FDA-approved indication(s) | Possible mechanism for anti-COVID-19 | Clinical trials ID (stage) | The highest anti-COVID-19 phase/ID/status/start-(estimated)end dates | References |
|-------------------------|--------------------|---------------------------|-------------------------------------|---------------------------|---------------------------------------------------------------|------------|
| Lactoferrin (protein)   | Anti-microbial, anti-inflammatory, and immunomodulatory | Anti-gram-negative, anti-gram-positive bacteria, fungi and viruses | Inhibiting the union of ACE2 with SARS-CoV-2 spike protein, blocking the heparan sulfate proteoglycan receptor | NCT04526821 (Phase 2) NCT04421534 (Phase 3) NCT04412395 (Phase 3) NCT04427865 (Phase 3) NCT04477971 (not applicable) NCT04475120 (Phase 3) NCT04713735 (not applicable) | Phase 3/NCT04475120/completed/April 15, 2020–July 2, 2020 | (Chang et al., 2020; Hu et al., 2021) |
| Propranolol             | Non-selective $\beta_1/\beta_2$-blocker | Hyperalgesia, social anxiety disorder, migraine headache, cigarette smoking, asthma, etc. | Blocking entry of SARS-CoV-2 through downregulation of the ACE2 receptor and CD147 | NCT04467086 (Phase 3) | Phase 3/NCT04467086/not yet recruiting/December 2020–April 2021 | (Vasanthakumar, 2020) |
| Linagliptin             | DPP-4 inhibitor | Diabetes mellitus, type 2 | Inhibiting DPP4, blocking DPP4 interacting with spike protein of the MERS-CoV | NCT04371978 (Phase 3) | Phase 3/NCT04371978/recruiting/October 1, 2020–June 30, 2021 | (Solerte et al., 2020) |
| Verapamil               | Calcium channel blocker and P-gp inhibitor, CYP3A4 inhibitor | Heart arrhythmias, high blood pressure and angina research | A slow-channel calcium-blocking agent. Blocking ion channels to inhibit coronavirus entry. | NCT04351763 (Phase 3) | Phase 3/NCT04351763/recruiting/April 27, 2020–March 2, 2021 | (Clinical trial ID: NCT04351763, n.d.) |
| Chlorpromazine          | Antagonist of dopamine D$_2$, 5-HT$_{2A}$, potassium channel and sodium channel. | Psychotic disorders such as schizophrenia. Glioblastoma multiforme | $K^+$/Na$^+$ channel inhibitor, inhibits clathrin-mediated endocytosis. | NCT04366739 (Phase 3) NCT04354805 (Phase 3) | Phase 3/NCT04366739/not yet recruiting/April 29, 2020–August 30, 2020 | (Plaze et al., 2020) |
| Dapagliflozin           | Competitive SGLT2 inhibitor | Diabetes mellitus (DM) | Reducing the viral load and preventing the lowering of cytosolic pH | NCT04350593 (Phase 3) | Phase 3/NCT04350593/active, not recruiting/April 22, 2020–April 2021 | (Cure & Cumhur Cure, 2020) |
| Nafamostat              | Serine protease inhibitor, Acute kidney injury | TMRE552 inhibitor | | NCT04390594 (Phase 3) NCT04352400 (Phase 3) NCT04418128 (Phase 3) | Phase 3/NCT04390594/recruiting/August 13, 2020–February 12, 2021 | (Fernandez-Fernandez et al., 2020) |
| Drug name and structure | Original mechanism | FDA-approved indication(s) | Possible mechanism for anti-COVID-19 | Clinical trials ID (stage) | The highest anti-COVID-19 phase/ID/status/start-estimated)end dates | References |
|-------------------------|--------------------|---------------------------|-------------------------------------|---------------------------|---------------------------------------------------------------|------------|
| Bicalutamide            | Non-steroidal AR antagonist | Prostate cancer, neoplasms, prostate. | Blocking TMPRSS2 | NCT04509999 (Phase 3) NCT04652765 (Phase 1) | Phase 3/NCT04509999/recruiting/October 26, 2020–September 2022 | (Cattrini et al., 2020) |
| Bromhexine              | Clearing mucus from respiratory tract, antioxidant | Chronic bronchitis, asthma and other causes of phlegm not easy to cough out | TMPRSS2 inhibitor | NCT04304349 (Early Phase1) NCT04424134 (Phase 3) NCT04355026 (Phase 4) NCT04273763 (not applicable) | Phase 4/NCT04355026/recruiting/April 10, 2020–June 30, 2020 | (Habtemariam et al., 2020; Maggio & Corsini, 2020) |
| Camostat                | Serine protease inhibitor, Corona virus infection, COVID-19, coagulopathy cardiovascular complication COVID-19 | TMPRSS2 inhibitor | Approximately 19 clinical trials, some of the examples are: NCT04353284 (Phase 2) NCT04524663 (Phase 2) NCT044583592 (Phase 2) NCT045608266 (Phase 3) NCT04455815 (Phase 3) NCT04657497 (Phase 2) | NCT04353284 (Phase 2) NCT04424134 (Phase 3) NCT04355026 (Phase 4) NCT04273763 (not applicable) | Phase 4/NCT0438906/withdrawn (lack of public funding)/June 1, 2020–December 2021 | (Huang et al., 2020) |
| Spironolactone          | AR antagonist | Heart failure, cardiomyopathy, alcoholic, alcoholism, osteoarthritis, Hypoglycemia, healthy | Inhibiting the androgen-dependent expression of TMPRSS2 | NCT04643691 (Phase 2) NCT04424134 (Phase 3) NCT044826822 (Phase 3) NCT04345887 (Phase 4) | Phase 4/NCT04345887/not yet recruiting/April 21, 2020–July 21, 2020 | (Cadegiani et al., 2020; Liaudet & Szabo, 2020) |
| Valsartan (diovan)      | AT II receptor antagonist | Hypertension stage 2 systolic hypertension | ACE2 inhibitor, inhibition of TMPRSS2 | NCT04335786 (Phase 4) | Phase 4/NCT0435786/recruiting/April 17, 2020–December 2020 | (Vitiello et al., 2020) |
| Arbidol (umifenovir)    | Antiviral agent | Influenza | Inhibition of ACE2/S protein interaction, blocking membrane fusion | NCT04350684 (Phase 4) NCT04260594 (Phase 4) NCT04476719 (Phase 1) | Phase 4/NCT04350684/enrolling by invitation/April 15, 2020–April 22, 2020 | (Clinical trial ID: NCT04260594, n.d.; Clinical trial ID: NCT04252885, n.d.; Huang et al., 2020) |

(Continues)
| Drug name and structure | Original mechanism | FDA-approved indication(s) | Possible mechanism for anti-COVID-19 | Clinical trials ID (stage) | The highest anti-COVID-19 phase/ID/status/start-estimated end dates | References |
|-------------------------|-------------------|-----------------------------|-------------------------------------|---------------------------|---------------------------------------------------------------|-----------|
| Proxalutamide (GT0918)  | Androgen receptor (AR) antagonist | COVID-19, Prostate cancer | ACE2 and TMPRSS2 levels in lung and cardiac cells are reduced by ant androgens | NCT04853134 (Phase 3) NCT04728802 (Phase 3) NCT04853927 (Phase 3) NCT05009732 (Phase 3) NCT04870606 (Phase 3) NCT04446429 (not applicable) | Phase 3/NCT04728802/completed/January 28, 2021–April 15, 2021 | (McCoy et al., 2021) |
| Canrenoate potassium    | Competitive mineralocorticoid receptor (aldosterone receptor) antagonist | Brain-dead organ donors, Cirrhosis, COVID-19 pneumonia | Pleiotropic effects with favorable renin-angiotensin-aldosterone system (RAAS) and ACE2 expression, reduction in transmembrane serine protease 2 (TMPRSS2) activity and antiandrogenic action | NCT04977960 (Phase 2) NCT04912011 (Phase 4) | Phase 4/NCT04912011/recruiting/June 3, 2021–August 31, 2021 | (Kotfis & Lechowicz, 2021) |
| Defibrotide              | Thrombotic microangiopathies, Kawasaki disease, Sickle cell disease | Coagulopathy | Mediated by the p38 MAPK pathway, which is upregulated as a result of the binding of SARS-CoV2 on ACE2 receptors on the surface of endothelial cells and, in turn, activates the transcription of the proinflammatory cytokines. | NCT04335201 (Phase 2) NCT04652115 (Phase 2) NCT04530604 (Phase 1) NCT04348383 (Phase 2) | Phase 2/NCT04335201/recruiting/April 6, 2020–June 20, 2021 | (Macciò et al., 2020) |
| Azithromycin             | Inhibit translation via interacting with 50S subunit of the bacterial ribosome | Acute bacterial, community-acquired pneumonia, uncomplicated skin infections, et al | Inhibiting viral invasion via interact with spike protein/CD147 interaction or blocking CD147 expression | Approximately 52 clinical trials, some of the examples are: NCT04334382 (Phase 3) NCT04371406 (Phase 3) NCT04359316 (Phase 4) NCT04339816 (Phase 3) NCT04332107 (Phase 3) NCT04621461 (Phase 4) NCT03871491 (Phase 3) | Phase 4/NCT04621461/completed/November 2020–February 8, 2021 | (Damle et al., 2020; Ulrich & Pillat, 2020) |
| Drug name and structure | Original mechanism | FDA-approved indication(s) | Possible mechanism for anti-COVID-19 | Clinical trials ID (stage) | The highest anti-COVID-19 phase/ID/status/start-(estimated)end dates | References |
|-------------------------|-------------------|---------------------------|--------------------------------------|---------------------------|---------------------------------------------------------------------|------------|
| Tetrandrine             | Voltage-gated Ca^{2+}-current (I_{Ca}) and Ca^{2+}-activated K^{+} current inhibitor | Corona virus disease 2019, COVID-19 | Inhibiting voltage-gated Ca^{2+} current (I_{Ca}) and Ca^{2+}-activated K^{+} current. | NCT04308317 (Phase 4) | Phase 4/NCT04308317/enrolling by invitation/March 5, 2020–March 1, 2021 (Clinical trial ID: NCT04308317, n.d.; Heister & Poston, 2020) |           |
| Doxycycline            | Broad-spectrum metalloproteinase (MMP) inhibitor | Anal chlamydia infection, rosacea, overactive bladder, HIV infections, sinusitis, acne vulgaris | Inhibition of the E2 envelope glycoprotein involved in virus entry | Approximately 10 clinical trials, some of the examples are: NCT04591600 (Phase 2), NCT04523831 (Phase 3), NCT04371952 (Phase 3), NCT04370782 (Phase 4), NCT04407130 (Phase 2), NCT04551755 (Phase 2), NCT04584567 (Phase 3) | Phase 4/NCT04370782/ completed/28, 2020–September 30, 2020 (Francini et al., 2020; Maurya, 2020) |           |
| Povidone-iodine         | Antibacterial agent (MRSA and MSSA strains) | External uses-infection; cesarean section, vaginal surgeries, arrhythmia | Interacting with surface proteins of enveloped viruses, destabilize membrane fatty acids, inducing cell apoptosis | Approximately 12 clinical trials, some of the examples are: NCT04410159 (Phase 2), NCT04549376 (Phase 2), NCT04510402 (Phase 2), NCT04371965 (Phase 2), NCT04872686 (Phase 3), NCT04344236 (Phase 2), NCT04603794 (Phase 4) | Phase 4/NCT04603794/recruiting/October 1, 2020–November 2020 (Pattanshetty et al., 2021) |           |
| Drug                        | Original mechanism                                      | FDA-approved indication(s) | Possible mechanism for anti-COVID-19                                                                 | Clinical trials ID (stage)                                                                 | The highest anti-COVID-19 phase/ID/status/start-(estimated) end dates                                                                 | References |
|-----------------------------|---------------------------------------------------------|----------------------------|---------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------|------------|
| Galidesivir                 | Viral RNA-dependent RNA polymerase (RdRP) inhibitor      | Not yet approved           | Inhibiting RNA dependent RNA polymerase                                                           | NCT03891420 (Phase 1)                                                                     | Phase 1/NCT03891420/recruiting/April 9, 2020–May 31, 2021                                                                      | (Elfiky, 2020; Silva Arouche et al., 2020) |
| Ebselen (PZ-51, SPI-1005, CCG-39161,) | Potent voltage-dependent calcium channel (VDCC) blocker | Not yet approved           | Inhibiting main protease via binding to M\(^{\text{pro}}\) from forming selenosulfide              | NCT04484025 (Phase 2) NCT04483973 (Phase 2)                                                | Phase 2/NCT04484025/not yet recruiting/May 2021–June 2022                                                                       | (Haritha et al., 2020; Ma et al., 2020) |
| Disulfiram (tetraethylthiuram disulfide; TETD) | Aldehyde-dehydrogenase (ALDH1) inhibitor                | Cocaine addictive, chronic alcoholism | Blocking the M\(^{\text{pro}}\) protease, inhibiting cytokine release induced by NF-kB and NLRP inflammasome | NCT04485130 (Phase 2) NCT04594343 (Phase 2)                                                | Phase 2/NCT04594343/recruiting/November 20, 2020–July 20, 2021                                                                | (Ma et al., 2020; Wang et al., 2003) |
| Tafenoquine                 | Anti-malarial prophylactic agent.                        | Not yet approved           | Inhibiting virus infection via down regulating M\(^{\text{pro}}\) activity                       | NCT04533347 (Phase 2)                                                                     | Phase 2/NCT04533347/recruiting/February 19, 2021–June 8, 2021                                                                     | (Chen, Yang, et al., 2020; Dow et al., 2020) |
| EIDD-2801 (Molnupiravir, MK-4482) | Virus RNA mutation                                      | Antivirus, not yet approved | Induced RNA mutagenesis by the viral RNA-dependent RNA polymerase (RdRp)                         | NCT04405739 NCT04392219 (Phase 1) NCT04575564 (Phase 3) NCT04405570 (Phase 2)            | Phase 3/NCT04575584/active, not recruiting/October 5, 2020–August 10, 2021                                                      | (Sheahan, Sims, Zhou, et al., 2020; PubChem, National Library of Medicine, n.d.; Kabinger & Stiller, 2021) |
| Merimepodib(MMPD, VX-497)   | Noncompetitive inosine monophosphate dehydrogenase (IMPDH) inhibitor | Not yet approved           | Inhibiting Zika viral RNA replication                                                             | NCT04410354 (Phase 2)                                                                     | Phase 2/NCT04410354/terminated (Failure to meet primary endpoint)/June 16, 2020–December 1, 2020                           | (X. Tong et al., 2018) |
| Clevudine (L-FMAU)          | Nucleoside analog of the unnatural L-configuration, non-competitive inhibitor that is not incorporated into the viral DNA but rather binds to the polymerase. | Chronic hepatitis B        | Inhibition of viral RNA synthesis                                                                | NCT04891302 NCT04347915 (Phase 2)                                                        | Phase 2/NCT04347915/recruiting/April 15, 2020–January 30, 2021                                                                   | (Hui & Lau, 2005; Jang et al., 2011) |
| Selinexor                   | Multiple myeloma                                         |                            |                                                                                                   |                                                                                           |                                                                                                                               | (Uddin et al., 2020) |
| Drug          | Original mechanism                                      | FDA-approved indication(s)                  | Possible mechanism for anti-COVID-19                                                   | Clinical trials ID (stage)                                                                 | The highest anti-COVID-19 phase/ID/status/start-(estimated) end dates | References                                                                 |
|--------------|--------------------------------------------------------|---------------------------------------------|-------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|--------------------------------------------------------------------------|--------------------------------------------------------------------------|
| Entecitabine | Nucleoside reverse transcriptase inhibitor (NRTI)       | HIV infection, PrEP adherence monitoring, healthy, hepatitis B | Reverse transcriptase inhibitor                                                          | NCT04712357 (not applicable) NCT04519125 (Phase 2) NCT04334928 (Phase 3) NCT04405271 (Phase 3) | Phase 3/NCT04405271/not yet recruiting/July 31, 2020–November 15, 2020 | (Ayerdi et al., 2020)                                                   |
| Tenofovir alafenamide | HIV-1 nucleotide reverse transcriptase inhibitor | HIV infections, hepatitis B. | Reverse transcriptase inhibitor                                                          | NCT04519125 (Phase 3) NCT04334928 (Phase 3) NCT04405271 (Phase 3) | Phase 3/NCT04405271/not yet recruiting/July 31, 2020–November 15, 2020 | (Duan et al., 2020)                                                   |
| Remdesivir   | Nucleoside analog with effective antiviral activity    | Not yet approved                            | Viral RNA-dependent RNA polymerase (RdRp) inhibitor, reducing viral multiplication      | Approximately 33 clinical trials, some of the examples are: NCT04539262 (Phase 2) NCT04610541 (Phase 3) NCT04501952 (Phase 3) NCT04292730 (Phase 3) NCT04560231 (Phase 1) NCT04672564 (Phase 3) NCT04480333 (Phase 1) | Phase 3/NCT04292899/completed/March 6, 2020–April 9, 2020 | (Coomes & Haghbayan, 2020; Wang, Cao, et al., 2020) |
| Ciclesonide  | Glucocorticoid receptor inhibitor                      | Obstructive airway diseases. Asthma, Allergic Rhinitis, Perennial | Inhibiting the replication of SARS-CoV-2 genomic RNA via targeting viral endonuclease NSP15 | NCT04330586 (Phase 2) NCT04435795 (Phase 3) NCT04377711 (Phase 3) NCT04381364 (Phase 2) NCT04356495 (Phase 3) | Phase 3/NCT04377711/completed/June 8, 2020–January 5, 2021 | (Kimura et al., 2020)                                                   |
| Ribavirin     | Nucleoside inhibitor                                  | HIV infections, hepatitis C               | RNA-dependent RNA polymerase inhibitor                                                   | Approximately 8 clinical trials, some of the examples are: NCT04828564 (Phase 3) NCT04563208 (Phase 2) NCT04494399 (Phase 2) NCT04460443 (Phase 3) NCT04356677 (Phase 1) NCT04392427 (Phase 3) | Phase 3/NCT04392427/not yet recruiting/October 2020–May 2022 | (S. Tong et al., 2020; Khalili et al., 2020) |
| Drug                        | Original mechanism                                                                 | FDA-approved indication(s)                                                                 | Possible mechanism for anti-COVID-19                                                                 | Clinical trials ID (stage)                                                                 | The highest anti-COVID-19 phase/ID/status/start-(estimated) end dates | References                                                                 |
|-----------------------------|------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|--------------------------------------------------------------------------|--------------------------------------------------------------------------|
| Dipyridamole                | Phosphodiesterase inhibitor                                                         | Cirrhosis, hypertension, status; splenectomy, venous thrombosis, brain ischemia, transient ischemic attack, arteriosclerosis, | Suppressing HCoV-19 replication                                                                       | NCT04391179 (Phase 2) NCT04424901 (Phase 2) NCT04410328 (Phase 3)                         | Phase 3/NCT04410328/recruiting/October 21, 2020–March 15, 2021          | (Liu, Li, Liu, Chen, & Luo, 2020; Liu, Zheng, Huang, Shan, & Huang, 2020; Ma & Wang, 2021) |
| Ivermectin                 | Anti-parasite agent, impα/β1-mediated nuclear import inhibitor                     | Healthy, rosacea, lymphatic filariasis, loiasis                                           | Blocking α/β1-mediated nuclear import                                                               | Approximately 56 clinical trials, some of the examples are: NCT04529525 (Phase 3) NCT04381884 (Phase 2) NCT04523831 (Phase 3) NCT04391127 (Phase 3) NCT04602507 (Phase 2) NCT04422561 (Phase 2) NCT04530474 (Phase 3) NCT04381884 (Phase 2) NCT04523831 (Phase 3) NCT04391127 (Phase 3) NCT04602507 (Phase 2) NCT04422561 (Phase 2) NCT04530474 (Phase 3) | Phase 3/NCT04523831/completed/June 1, 2020–August 22, 2020              | (Heidary & Gharebaghi, 2020; Sharun et al., 2020)                        |
| Rosuvastatin               | HMG-CoA reductase enzyme inhibitor, cholesterol level inhibitor, block hERG current | Dyslipidemias, non-ST-elevation acute coronary syndromes, cardiovascular disease, myocardial infarction, hypercholesterolemia | Targeting COVID-19 virus MPro                                                                     | NCT04472611 (Phase 3)                                                                          | Phase 3/NCT04362137/not yet recruiting/August 1, 2020–August 1, 2021  | (Farag et al., 2020)                                                   |
| Isoquercetin (Quercetin 3-glucoside, IQC-950AN) | Regulates the expression of nitric oxide synthase 2 (NO2) via modulating the nuclear factor-xB (NF-xB) transcription regulation system | Cardiovascular disease, chronic kidney disease, Covid19                                    | MPro inhibitor                                                                                     | NCT04536090 (Phase 2) NCT04733651 (Phase 2) NCT04622865 (Phase 2)                      | Phase 2/NCT04622865/recruiting/November 10, 2020–June 2021            | (Saeedi-Boroujeni & Mahmoudian-Sani, 2021)                                |
| Ritonavir                  | HIV type 1aspartate protease inhibitor                                             | HIV infection                                                                             | Inhibit the coronaviral 3CLPro protease                                                            | Approximately 24 clinical trials, some of the examples are: NCT04403100 (Phase 3) NCT04321174 (Phase 3) NCT04291729 (Phase 4) NCT04345276 (Phase 4) NCT04261270 (Phase 3) NCT04386876 (Phase 1) NCT04466241 (Phase 2) | Phase 4/NCT04291729/completed/February 17, 2020–March 19, 2020            | (Cao et al., 2020; Chu et al., 2004; Li & De Clercq, 2020; Ma et al., 2021; Shehahan, Sims, Leist, et al., 2020; Zhang, Lin, et al., 2020) |
| Drug                  | Original mechanism                  | FDA-approved indication(s)                                                                 | Possible mechanism for anti-COVID-19                  | Clinical trials ID (stage)                                                                 | The highest anti-COVID-19 phase/ID/status/start-(estimated) end dates                                                                 | References |
|----------------------|-------------------------------------|--------------------------------------------------------------------------------------------|---------------------------------------------------|------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------|------------|
| Etoposide (VP-16; VP-16-213) | Topoisomerase II inhibitor            | Adult acute lymphocytic leukemia, NK + T Cell lymphoma, mantle cell lymphoma, small cell lung cancer | SARS-3CL protease inhibitor                       | NCT04356690 (Phase 2)                                                                   | Phase 2/NCT04356690/Active, not recruiting/April 22, 2020–December 2021                                                      | (Rashid et al., 2022) |
| PF-07321332          | SARS-CoV 3C-like protease (3CLPRO) inhibitor | COVID-19                                                                                     | 3CLpro inhibitor                                   | NCT04960202 (Phase 3) NCT04962230 (Phase 1) NCT05035312 (Phase 1) NCT04909853 (Phase 1) | Phase 3/NCT04960202/recruiting/July 13, 2021–October 16, 2021                                                               | (Vandyck & Deval, 2021) |
| PF-07304814          | Potent 3CLpro protease (Mpro) inhibitor | Viral disease                                                                                | 3CLpro protease inhibitor                          | NCT04535167 (Phase 1) NCT04627532 (Phase 1)                                             | Phase 1/NCT04627532/completed/November 13, 2020–December 17, 2020                                                           | (Boras, 2021; Vandyck & Deval, 2021) |
| Lopinavir            | HIV type 1 aspartate protease inhibitor | HIV infection                                                                               | Inhibit the viral proteases: 3CLpro or Prpro, increasing t1/2 via inhibiting cytochrome P450 when combined with lopinavir | Approximately 18 clinical trials, some of the examples are: NCT04403100 (Phase 3) NCT04307693 (Phase 2) NCT04321174 (Phase 3) NCT04455998 (Phase 2) NCT04255017 (Phase 4) NCT0430690 (Phase 2) NCT04368676 (Phase 1) | Phase 4/NCT04255017/recruiting/February 1, 2020–June 1, 2020                                                                | (Cao et al., 2020; Chu et al., 2004; Li & De Clercq, 2020; Ma et al., 2021; Sheahan, Sims, Leist, et al., 2020; Zhang, Lin, et al., 2020) |
| Oseltamivir          | Virus neuraminidase enzyme inhibitor  | Influenza A and B viruses                                                                    | Virus-release blockers                              | NCT04303299 (Phase 3) NCT04558463 (Phase 3) NCT04516915 (Phase 3) NCT04255017 (Phase 4) NCT02735707 (Phase 4) NCT0438698 (Phase 3) | Phase 4/NCT04255017/recruiting/February 1, 2020–June 1, 2020                                                                | (Akram et al., 2020; Clinical trial ID: NCT04255017, n.d; Whitley, 2007) |
| Drug                  | Original mechanism                                                                 | FDA-approved indication(s) | Possible mechanism for anti-COVID-19                                                                 | Clinical trials ID (stage)                                                                 | The highest anti-COVID-19 phase/ID/status/start-estimated end dates | References                                                                 |
|----------------------|-------------------------------------------------------------------------------------|-----------------------------|-----------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|-----------------------------------------------------------------------|---------------------------------------------------------------------------|
| Favipiravir          | Viral RNA polymerase inhibitor                                                     | Influenza                   | RNA dependent RNA polymerase inhibitor, reducing virus replication                                 | Approximately 38 clinical trials; some of the examples are: NCT04402203 (Phase 3)        | Phase 4/NCT04359615/not yet recruiting/April 20, 2020–May 3, 2020    | (Coomes & Haghbayan, 2020; Wang, Cao, et al., 2020)                      |
| Ledipasvir           | Inhibitor of the hepatitis C virus NSSA                                            | Hepatitis C, hepatocellular carcinoma | RdRP inhibitor                                                                                     | NCT04498936 (Phase 4) NCT04530422 (Phase 3)                                               | Phase 4/NCT04498936/sofosbuvir/ledipasvir and nitazoxanide for treatment of COVID-19 | (Mevada et al., 2020; Sayad et al., 2020)                                |
| Sofosbuvir           | HCV RNA replication inhibitor                                                      | Hepatitis C, liver cirrhosis | RdRP inhibitor                                                                                     | Approximately 8 clinical trials; some of the examples are: NCT04530422 (Phase 3)         | Phase 4/NCT04498936/completed/July 15, 2020–October 30, 2020            | (Ju et al., 2020; Elfiky, 2020; Sayad et al., 2020)                      |
| GS-441524            | Inhibits feline infectious peritonitis virus (FIPV), parent nucleoside of remdesivir | COVID-19                    | Interferes with the SARS-CoV-2 RNA-dependent RNA polymerase (RdRp)                                | NCT04859244 (Phase 1)                                                                     | Phase 1/NCT04859244/completed/April 26, 2021–May 1, 2021              | (Yan & Muller, 2020)                                                    |
| AT-527 (R07496998)   | HCV viral replication inhibitor                                                   | HCV Infection               | Inhibit the RdRp for RNA synthesis                                                                | NCT04889040 (Phase 3) NCT04709835 (Phase 2) NCT04396106 (Phase 2) NCT04877769 (Phase 1) | Phase 3/NCT04889040/recruiting/May 17, 2021–August 3, 2021             | (Good et al., 2021)                                                     |
interleukins, tumor necrosis factors (TNF), chemokines, and several other mediators), resulting in a clinical presentation of unrelenting high fever, hyperferritinemia, hepatosplenomegaly, cytopenia, lymphadenopathy and central nervous system abnormalities, and, if untreated, could lead to the organ failure and even the death (Fajgenbaum & June, 2020; Gao et al., 2021). Abundant studies have revealed that majority of COVID-19 patients are often have higher levels of inflammatory mediators in blood. Those inflammatory mediators include cytokines and chemokines such as interleukin (IL)-1, IL-6, IL-7, IL-10, IL-21, TNF, and monocyte chemoattractant protein-1 (MCP1, also known as CCL2) etc. (Chen, Wu, et al., 2020; Gorbalenya et al., 2020; Hojyo et al., 2020; Tay et al., 2020). Therefore, COVID-19 could be featured as a cytokine release syndrome (CRS) and the fatality could be caused by the high mortality cytokine storm. In fact, the approach on addressing the CSS for the potential treatment of COVID-19 is currently investigated in clinics. For example, physicians apply medicines such as corticosteroids (prednisone, methylprednisolone, and hydrocortisone), interleukin inhibitors (anakinra, levamisole, and colchicine), and JAK–STAT inhibitors (ruxolitinib and baricitinib) to patients to see whether these medicines could alleviate the symptoms of COVID-19. Studies suggest that suppressing the release of cytokine could probably improve the clinical outcomes (L. Lu et al., 2020). However, the adverse consequences were also observed in patients when corticosteroid therapy was applied during COVID-19 infection. Thereby, it is important to strictly control the time and dosage of glucocorticoids administration in the disease prognosis (Sanders et al., 2020). Glucocorticoids are mainly used in severe patients with CSS (Ye et al., 2020). The WHO currently does not recommend the routine use of corticosteroids in COVID-19 patients, due to the potential delay in viral clearance. Hence, corticosteroids should be given to patient with certain symptoms such as severe acute respiratory distress syndrome or refractory septic shock (Mehta, Mazer-Amirshahi, et al., 2020). Agents in clinical trials for potential inhibiting cytokine storm in COVID-19 are summarized in Table 3.

### Table 2 (Continued)

| Drug          | Original mechanism inhibitor | FDA-approved indication(s) | Clinical trials ID (stage) | Possible mechanism for anti-COVID-19 | Reference(s) |
|---------------|------------------------------|----------------------------|---------------------------|-------------------------------------|--------------|
| Darunavir     | HIV protease inhibitor        | HIV infections, healthy    | NCT04252274 (Phase 3)    | Protease inhibitor                  | Kutli & Metin, 2020; Papic et al. 2020 |
|               |                              |                            | NCT04435587 (Phase 4)    |                                     | (Kutli & Metin, 2020; Papic et al. 2020) |
|               |                              |                            | NCT04303299 (Phase 3)    |                                     |              |

2.4 Modulating immune system

Special cells (such as white blood cells B- and T-lymphocytes), organs (such as bone marrow, spleen, and thymus), and chemicals (antibodies) mainly compose the immune system (Sompayrac, 2019). The well-working immune system produces antibodies to kill pathogens and protects the body against viruses and diseases. The immune system in human body plays a fundamental role in maintaining health (Chowdhury et al., 2020). After invasion into the human body, SARS-CoV-2 will encounters a robust innate immune response when it moves to the respiratory tract (Rokni et al., 2020; Tang et al., 2005). The immune system plays a critical role in the body’s defenses against SARS-CoV-2 infection. Immune system modulation prevents tissue damage resulting from an excessive response. Under some circumstances, drugs modulating immune system could be an efficient strategy for fighting against COVID-19. Agents such as cyclosporine A, isoprinosine, all-trans retinoic acid are in clinical trials aiming to
suppress the virus infection through modulation of the immune system (Table 4).

2.5 | Anticoagulant therapy

SARS-CoV-2 can invade cells lining blood vessels and cause a series of consequences related to cardiovascular diseases and thrombosis. More specifically, the virus invasion could induce endothelial dysfunction which further leads to pulmonary thrombosis (Carfora et al., 2021; Poissy et al., 2020). Applying anticoagulant therapy in COVID-19 patients has scientific support and is in line with the COVID-19 global pandemic emergency. Agents such as rivaroxaban and apixaban are in ongoing clinical trials to combat COVID-19 associated hypercoagulation (Figure 2 and Table 5). The efficacy and effectiveness of using anticoagulant therapy for COVID-19 await clinical data.

2.6 | Antioxidant supplement

Antioxidant agents help prevent free radicals or reactive oxygen species (ROS) from harming healthy cells in human body. The effects of antioxidants on heart disease, cancer, and arthritis have been widely studied. As a powerful antioxidant, vitamin-C might protect the human body against SARS-CoV-2 infection through its important role in enhancing human body immunity (Carr & Maggini, 2017). A high-dose vitamin C in coping with the oxidative stress in COVID-19 patients is currently being studied (Colunga Biancatelli et al., 2020; Hunt et al., 1994). In addition, vitamin D supplementation might lower the odds of developing respiratory infections according to the data from observational studies (Table 6) (Martineau et al., 2017; McCartney & Byrne, 2020)

3 | AGENTS IN THE DRUG DEVELOPMENT PHASES OF THE PIPELINE

Approved drugs or clinical candidates in COVID-19 clinical trials are arranged and analyzed based on their highest stage of clinical trial. A summary of the drug name, structure, class, original mechanism, FDA-approved indication(s), possible mechanism for COVID-19 treatment, the highest anti-COVID-19 phase (clinical trial ID) etc. are presented in this section (Figure 4 and Tables 1–6).

3.1 | Phase I/II clinical candidates

The primary goal of Phase I study is to assess the safety, the tolerability, the pharmacokinetic parameters, and the pharmacodynamics effects of a drug candidate in healthy volunteers. At the end of this phase, the optimum dose and formulation will be determined. The information obtained could be used for subsequent phases. There are four agents in Phase I clinical trials (Figure 4). PF-07304814 is an inhibitor of 3CLpro currently in several clinical stages including Phase I. Galidesivir and GS-441524, RdRP inhibitors, are being tested in Phase I for potential blocking viral replication. Progesterone, a steroid hormone, aims to address the CSS. No small molecule in other categories is currently in phase I trials. It takes a long time to develop a new drug from scratch, so researchers focus their main efforts on drug repurposing.

A phase II trial is designed to obtain the therapeutic effects and side effects of the drug candidate in patients with the disease. In contrast to only two trials in phase I, there are significantly more trials in phase II. The drugs for phase II trials are all FDA-approved drugs for indications other than COVID-19. In fact, there are 42 agents in approximately 85 phase II trials (Figure 4).

There are 5 small molecules in phase II trials aiming to block virus-cell membrane fusion and entry, 8 small molecules inhibiting the viral replication, 23 small molecules addressing cytokine storm, 5 small molecules modulating the immune system, and 1 small molecule used as anticoagulant therapy. There is no small molecule phase II trial using antioxidant supplement.

Of the drugs blocking virus-cell membrane fusion and entry, there are three agents (ramipril and atovaquone and defibrotide) targeting ACE, one agent (enlutamide) acting as androgen receptor (AR) antagonist aiming to block TMPRSS2, the other agent (maraviroc) acting as CCR5 antagonist inhibiting cell fusion. Of the drugs targeting viral replication, there were four Mpro protease inhibitors (ebeselen, disulfiram, tafenoquine and isoquercetin). Ebselen and disulfiram are nonspecific promiscuous SARS-CoV-2 main protease inhibitors, one 3CLpro inhibitor (etoposide), two agents (, merimepodib and clevudine) targeting RNA, one agent (selinexor) inhibiting virus assembly processes. Of the drugs addressing CSS, there were three Bruton’s tyrosine kinase (BTK) inhibitors (zanubrutinib, acalabrutinib, and ibrutinib), one phosphatidylinositol 3-kinase (PI3K) inhibitor (duvelisib), one mTOR inhibitor (sirolimus), one agent (enapotaran) blocking the activation of Toll-like receptor 7 (TLR7) and TLR8, 8 agents (artemic, abivertinib, estradiol, pentoxyffyline, aprepitant, prazosin, PF-06650833 and ampon) mediating the release of inflammatory cytokines, 9 agents (ibudilast, LAU-7b, naltrexone, piclidenoson, clarithromycin, thalidomide, EC-18, APX-115 and cenicriviroc) are anti-inflammatory drugs. Of the drugs modulating the innate immune system, there are four agents: methotrexate, leflunomide, fingolimod, and tamoxifén. There is only one agent (ketamine) used for symptomatic control.

3.2 | Phase III clinical candidates

Phase III clinical trials are the studies in the efficacy confirmatory stage. Its goal is to further verify the therapeutic effectiveness and the safety of a drug candidate on patients with specific indications, and to assess the overall risk–benefit relationships. The results from this stage trial will ultimately provide substantial ground for the new drug registration applications. In this stage of the trial, a larger array of trials and more patients will be required and assessed than those trials in phase II
| Drug name and structure | Original mechanism | FDA-approved indication(s) | Possible mechanism for anti-COVID-19 | Clinical trials ID (stage) | The highest anti-COVID-19 phase/ID/status/ start-(estimated)end dates | References |
|------------------------|-------------------|---------------------------|-------------------------------------|---------------------------|-------------------------------------------------------------------|------------|
| Progesteron            | Steroid hormone regulating menstrual cycle | Suicidal ideation, infertility, hormone replacement, concussion | Inhibiting pro-inflammatory cytokines IL-1β and IL 12 | NCT04365127 (Phase 1) | Phase1/NCT04365127/ completed/April 27, 2020–August 20, 2020 | Mauvais-Jarvis et al., 2020 |
| Acalabrutinib         | BTK inhibitor | Not yet approved | BTK inhibitor, decreased inflammatory cell infiltration and proinflammatory cytokines | NCT04380688(Phase 2) NCT04346199(Phase 2) NCT04497948(Phase 1) NCT04564040(Phase 1) | Phase 2/NCT04346199/ completed/June 12, 2020–November 17, 2020 | Roschewski et al., 2020 |
| Ibrutinib             | Irreversible BTK inhibitor | Lymphocytic, waldenstrom macroglobulinemia, mantle-cell, B-cell, etc. | BTK inhibitor, decreasing inflammatory cell infiltration and proinflammatory cytokines | NCT04375397 (Phase 2) NCT04665115 (Phase 2) NCT04439006 (Phase 2) | Phase 2/NCT04439006/ recruiting/July 22, 2020–December 31, 2021 | Treon et al., 2020 |
| Zanubrutinib         | Selective BTK inhibitor | Not approved yet | BTK inhibitor, decreased inflammatory cell infiltration and proinflammatory cytokines | NCT04382586 (Phase 2) | Phase 2/NCT04382586/ active, not recruiting/July 6, 2020–February 2, 2021 | Chong et al., 2020 |
| Duvelisib             | Selective p100δ inhibitor | Not approved yet | Inhibiting phosphatidylinositol 3-kinase (PI3K) which plays a crucial role in eliciting immune response. | NCT04372602 (Phase 2) NCT04487886 (Phase 2) | Phase 2/NCT04372602/ recruiting/October 12, 2020–November 30, 2021 | (Clinical trial ID: NCT04487886, n.d.) |
| Sirolimus (rapamycin) | mTOR inhibitor | Kidney transplantation, blue rubber bleb nevus syndrome, venous malformation, kidney transplantation, uterine fibroids | Alleviating cytokine strom and T-cell senescence, preventing severe COVID-19 progression | Approximately 7 clinical trials, some of the examples are: NCT04461340 (Phase 2) NCT04371640 (Phase 1) NCT04341675 (Phase 2) NCT04409327 (Phase 2) | Phase 2/NCT04341675/ recruiting/April 24, 2020–July 2020 | Omarjee et al., 2020 |

(Continues)
| Drug name and structure          | Original mechanism                                      | FDA-approved indication(s)          | Possible mechanism for anti-COVID-19                                                                 | Clinical trials ID (stage)                                                                 | The highest anti-COVID-19 phase/ID/status/start-(estimated)end dates | References                                                                 |
|--------------------------------|----------------------------------------------------------|-------------------------------------|-----------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|--------------------------------------------------------------------------|--------------------------------------------------------------------------|
| ArtemiC (artemisinin, curcumin, frankincense and vitamin C) | Anti-inflammation                                      | Not currently approved              | Diminishing activity of TNF-α and IL-6 levels                                                  | NCT04382040 (Phase 2)                                                                  | Phase 2/NCT04382040/completed/May 8, 2020–November 2020/MGC pharmaceuticals d.o.o) | (Clinical trial ID: NCT04382040, n.d.)                                   |
| Abivertinib                    | Tyrosine kinase inhibitor (TKI), BTK Inhibitor, third-generation EGFR tyrosine kinase inhibitor | Not yet approved                    | Inhibition of vital pro-inflammatory cytokine production, such as IL-6, IL-1β and TNF-α          | NCT04528667 (Phase 2)                                                                  | Phase 2/NCT04528667/recruiting/September 2020–May 2021                 | (Clinical trial ID: NCT04440007, n.d.; Sorrento Therapeutics Inc, News Release, 2020) |
| Estradiol                      | Enhancing expression of interleukin 6 via the estrogen receptor β (ERβ) pathway | Menorrhagia, vaginal atrophy, healthy, suicidal ideation | Anti-inflammatory and immunomodulatory, blocking the proinflammatory cytokines production, such as IL-6, IL-1β, TNF-α and chemokine CCL2 | NCT04359329 (Phase 2)                                                                | Phase 2/NCT04359329/recruiting/April 20, 2020–November 15, 2020       | (Mauvais-Jarvis et al., 2020)                                           |
| Pentoxifylline                 | Competitive nonselective phosphodiesterase inhibitor    | Type 2 diabetes, chronic renal failure, severe alcoholic hepatitis, lupus nephritis, irritable bowel syndrome, diabetic kidney disease et al. | Anti-inflammatory, blocking the proinflammatory cytokines production, such as IL-6, IL-1, TNF-α, C-reactive protein and other immunoregulators. | NCT04433988 (Phase 2)                                                                  | Phase 2/NCT04433988/not yet recruiting/December 13, 2020–December 30, 2021 | (Assimakopoulos et al., 2020; González-Pacheco et al., 2020)             |
| Deferoxamine                   | Iron chelator                                            | Iron overload, diabetic foot ulcer, acute ischemic stroke, Beta-Thalassemia                          | Inhibiting IL-6 synthesis through decreasing NF-kB.                                              | NCT04333550 (Phase 2)                                                                  | Phase 4/NCT04389801/not yet recruiting/May 15, 2020–September 30, 2020 | (Clinical trial ID: NCT04389801, n.d.; Dalamaga et al., 2020)             |
| Cefditoren (Pivoxil, ME 1207)  | New-third generation cephalosporin antibiotic, broad spectrum of activity against Gram-positive and gram-negative bacteria | Rhinosinusitis, COVID-19 pneumonia, urinary tract infections                                     | Decrease IL-6 level and other pro-inflammatory cytokines                                          | NCT04709172 (Phase 4)                                                                | Phase 4/NCT04709172/recruiting/January 14, 2021–April 5, 2021           | (Clinical trial ID: NCT04709172, n.d.)                                   |
| Drug name and structure | Original mechanism | FDA-approved indication(s) | Possible mechanism for anti-COVID-19 | Clinical trials ID (stage) | The highest anti-COVID-19 phase/ID/status/start-(estimated)end dates | References |
|------------------------|--------------------|---------------------------|--------------------------------------|---------------------------|---------------------------------------------------------------|------------|
| Aprepitant (cinvanti)  | Neurokinin 1 receptor antagonist | Postoperative nausea and vomiting, healthy volunteers, emesis, breast cancer, leukemia | Anti-inflammatory, blocking inflammatory cytokines release mediated by the binding of substance P to NK1 receptors | NCT04470622 (Phase 2) | Phase 2/NCT04470622/recruiting/July 20, 2020–June 2021/ Heron Therapeutics | (Clinical trial ID: NCT04470622, n.d.; Mehboob et al., 2020) |
| Prazosin               | Selective alpha 1-adrenergic blocking agent. | PTSD, panic disorder, hypertension and anxiety and anxiety | α-1 adrenergic receptor antagonist, prevent cytokine storm | NCT04365257 (Phase 2) | Phase 2/NCT04365257/recruiting/May 13, 2020–June 30, 2021 | (Konig et al., 2020) |
| Ampion (DA-DKP, aspartyl-alanyl diketopiperazine) | Modulating inflammatory immune response via molecular pathways related to T lymphocyte energy deficiency | Inflammation associated with osteoarthritis | Anti-inflammatory, blocking the pro-inflammatory cytokines production in T-cells | NCT04456452 (Phase 1) NCT04839965 (Phase 2) NCT04606784 (Phase 1) | Phase 2/NCT04839965/recruiting/April 2021–October 2021 | (Clinical trial ID: NCT04414618, n.d.) |
| Ibudilast              | Nonselective phosphodiesterase inhibitor | Asthma, multiple sclerosis | Anti-inflammatory | NCT04429555 (Phase 2) | Phase 2/NCT04429555/recruiting/November 2020–June 30, 2021 | (Clinical trial ID: NCT04429555, n.d.) |
| LAU-7b (fenretinide [4-HPR]) | Retinoic acid receptors (RAR) inhibitor | Not approved yet | Anti-inflammatory and antiviral activities | NCT04417257 (Phase 2) | Phase 2/NCT04417257/recruiting/June 29, 2020–May 15, 2021 | (Orienti et al., 2020) |
| Naltrexone             | Blockade of opioid receptors, κ-opioid receptor antagonist | Alcoholism, opioid use, obesity | Interrupt the inflammation | NCT04365985 (Phase 2) NCT04756128 (Phase 2) NCT04604678 (Phase 2) NCT04604704 (Phase 2) NCT04708327 (Phase 2) | Phase 2/NCT04365985/recruiting/April 29, 2020–May 15, 2021 | (Choubey et al., 2020) |
| Piclidenoson           | Adenosine A3 receptor agonist | Not approved yet | Anti-inflammatory | NCT04333472 (Phase 2) | Phase 2/NCT04333472/recruiting/January 6, 2021–March 6, 2022 | (David & Shweta, 2020) |

(Continues)
| Drug name and structure | Original mechanism | FDA-approved indication(s) | Possible mechanism for anti-COVID-19 | Clinical trials ID (stage) | The highest anti-COVID-19 phase/ID/status/estimated end dates | References |
|-------------------------|--------------------|--------------------------|-------------------------------------|---------------------------|----------------------------------------------------------|------------|
| Clarithromycin          | Macrolide antibiotic and a CYP3A4 inhibitor | Antibiotics-bacterial infection, nontuberculous mycobacteria, mycobacterium avium complex, crohn’s disease, ulcer, peptic ulcer, periodontitis | Anti-inflammatory nature and enhance the immunity | NCT04398004 (Phase 2) NCT04622891 (not applicable) | Phase 2/NCT04398004/ completed/May 6, 2020–November 30, 2020 | (Chalichem et al., 2020; Millán-Oñate et al., 2020) |
| Thalidomide            | Cereblon (CRBN) inhibitor, sedative, part of the cullin-4 E3 ubiquitin ligase complex CUL4-RBX1-DDB1 | Mantle cell lymphoma, NSCLC, congestive heart failure, multiple myeloma, gastric cancer | Anti-inflammatory and anti-fibrosis | NCT04273581 (Phase 2) NCT04273529 (Phase 2) | Phase 2/NCT04273581/ not yet recruiting/February 18, 2020–April 30, 2020 | (Khalil et al., 2020) |
| Cenicriviroc           | Dual CCR2/CCR5 antagonist | Not yet approved | Anti-inflammatory and immunomodulatory effects | NCT04500418 (Phase 2) | Phase 2/NCT04500418/ recruiting/August 25, 2020–September 30, 2021 | (Okamoto et al., 2020) |
| Ruxolitinib            | Selective JAK1/2 inhibitor | Thalassemia major, splenomegaly | Inhibit the downstream IFNγ pathway targeting JAK kinase receptor | Approximately 19 clinical trials, some of the examples are: NCT04414098 (Phase 2) NCT04477993 (Phase 3) NCT04581954 (Phase 2) NCT04362137 (Phase 3) NCT04348071 (Phase 3) NCT04377620 (Phase 3) NCT04338958 (Phase 2) | Phase 3/NCT04362137/ completed/May 2, 2020–October 17, 2020 | (Goker Bagca & Biray Avci, 2020; Neubauer et al., 2020) |
| Baricitinib            | JAK1 and JAK2 inhibitor | Rheumatoid arthritis | JAK–STAT signal blocking | Approximately 11 clinical trials, some of the examples are: NCT04358614 (Phase 3) NCT04320277 (Phase 3) NCT04340232 (Phase 3) NCT04373044 (Phase 2) NCT04421027 (Phase 3) NCT04346147 (Phase 2) NCT04832880 (Phase 3) | Phase 3/NCT04421027/ recruiting/Jun 12, 2020–May 19, 2021 | (Cantini et al., 2020; Favalli et al., 2020) |
| Drug name and structure | Original mechanism | FDA-approved indication(s) | Possible mechanism for anti-COVID-19 | Clinical trials ID (stage) | The highest anti-COVID-19 phase/ID/status/start (estimated) end dates | References |
|------------------------|-------------------|---------------------------|--------------------------------------|---------------------------|---------------------------------------------------------------|------------|
| Niclosamide            | Anti-parasitic drug, STAT3 inhibitor, DNA replication inhibitor | Not yet approved | Blocking signaling pathways including mTORC1, IL-6-JAK1-STAT3 signaling | Approximately 13 clinical trials, some of the examples are: NCT04558021 (Phase 3) NCT04399356 (Phase 2) NCT04542434 (Phase 2) NCT04372082 (Phase 3) NCT04603924 (Phase 3) NCT04436458 (Phase 2) NCT04524052 (Phase 1) | Phase 3/NCT04558021/recruiting/October 8, 2020–January 30, 2021 | (Pindiprolu & Pindiprolu, 2020; Xu, Shi, Wang, et al., 2020) |
| Levamisole             | Anthelmintic and immunomodulator | Broad-spectrum insect repellent | Down regulating the level of IL-6 and TNF-α | NCT04360122 (Phase 3) NCT04383717 (Phase 3) NCT04331470 (Phase 3) | Phase 3/NCT04331470/recruiting/April 4, 2020–April 20, 2020 | (Uyaroglu et al., 2020) |
| Opaganib               | Selective, competitive sphingosine kinase 2 (SK2) inhibitor | Not yet approved | Down regulating the level of IL-6 and TNF-α, inhibiting viral replication | NCT044414618 (Phase 2) NCT04467840 (Phase 3) NCT04502069 (Phase 2) | Phase 3/NCT04467840/recruiting/August 21, 2020–June 2021 | (Kurd et al., 2020) |
| Anakinra               | Interleukin-1 receptor (IL-1) antagonist | Rheumatoid arthritis, knee injuries | Interleukin-1 (IL-1) blockage | Approximately 17 clinical trials, some of the examples are: NCT04826588 (Phase 3) NCT04364009 (Phase 3) NCT04443881 (Phase 3) NCT04603742 (Phase 2) NCT04357366 (Phase 2) NCT04339712 (Phase 2) NCT04412291 (Phase 2) | Phase 3/NCT04443881/recruiting/May 8, 2020–December 2020 | (Gallelli et al., 2020) |
| PF-06650833            | Interleukin-1 receptor associated kinase 4 (IRAK4) inhibitor | Rheumatoid arthritis, lupus, lymphomas | Inhibition of interleukin-1 receptor associated kinase 4 (IRAK4) in ameliorating the proinflammatory state and improving outcomes in severe COVID-19. | NCT04933799 (Phase 2) | Phase 2/NCT04933799/recruiting/June 22, 2021–March 6, 2022 | (Clinical trial ID: NCT04933799, n.d.) |

(Continues)
| Drug name and structure | Original mechanism | FDA-approved indication(s) | Possible mechanism for anti-COVID-19 | Clinical trials ID (stage) | The highest anti-COVID-19 phase/ID/status/start (estimated)end dates | References |
|-------------------------|--------------------|----------------------------|--------------------------------------|---------------------------|---------------------------------------------------------------------|------------|
| Atorvastatin | HMG-CoA reductase inhibitor | Stable angina, acute coronary syndrome, hepatocellular carcinoma, cardiovascular disease, ischemia et al. | lower levels of inflammatory cytokines | NCT04466241 (Phase 2) NCT04380402 (Phase 2) NCT04486508 (Phase 3) | Phase 3/NCT04486508/active, not recruiting/July 30, 2020–April 4, 2021 | (Ghati et al., 2020; Li, 2020; Tan et al. 2020) |
| PTC299 | Dihydroorotate dehydrogenase (DHODH) inhibitor | Not yet approved | Blocking the proinflammatory cytokines production such as IL-6, IL-17, IL-17F | NCT04439071 (Phase 3) | Phase 3/NCT04439071/recruiting/July 9, 2020–January 30, 2021 | (Luban et al., 2021) |
| Amiodarone | ATP-sensitive potassium channel inhibitor | Atrial fibrillation, atrial fibrillation, new onset atrial fibrillation, paroxysmal atrial fibrillation, ventricular Tachycardia et al. | Anti-inflammatory action against the key cytokines involved in the cytokine storm | NCT04351763 (Phase 3) | Phase 3/NCT04351763/recruiting/April 27, 2020–March 2, 2021 | (Sanchis-Gomar et al., 2020) |
| VERU-111 | Orally bioavailable α and β tubulin inhibitor | Metastatic castration resistant prostate cancer | Anti-inflammatory action against the key cytokines involved in the cytokine storm | NCT04388826 (Phase 2) NCT04842747 (Phase 3) | Phase 3/NCT04842747/not yet recruiting/April 30, 2021–January 5, 2022 | (Clinical trial ID: NCT04388826, n.d.) |
| Escin | Vasoprotective anti-inflammatory, anti-nociceptive and anti-edematous agent. | Chronic venous insufficiency | Vasoprotective anti-inflammatory | NCT04322344 (Phase 2) | Phase 3/NCT04322344/recruiting/March 23, 2020–June 30, 2020 | (Clinical trial ID: NCT04322344, n.d.; Gallelli et al., 2020) |
| Imatinib | Tyrosine kinases inhibitor | Breast cancer, gastrointestinal stromal tumors, chronic myeloid leukemia | Tyrosine kinase inhibitors in the regulation of inflammation | NCT04794088 (Phase 2) NCT04422678 (Phase 3) NCT04394416 (Phase 3) NCT04357613 (Phase 2) NCT04346147 (Phase 2) | Phase 3/NCT04394416/recruiting/June 2, 2020–June 1, 2022 | (Sisk et al., 2018) |
| Montelukast | Cysteinyl leukotriene receptor 1 (Cysltr1) antagonist | Asthma and liver injury, reduce cardiac damage | Anti-inflammatory, reducing production of cytokine | NCT04714515 (Phase 3) NCT04389411 (Phase 3) NCT04695704 (Phase 3) NCT04718285 (Phase 2) | Phase 3/NCT04714515/completed/February 20, 2020–March 30, 2020 | (Bozek & Winterstein, 2020; Fidan & Aydogdu, 2020) |
| Drug name and structure | Original mechanism | FDA-approved indication(s) | Possible mechanism for anti-COVID-19 | Clinical trials ID (stage) | The highest anti-COVID-19 phase/ID/status/start-(estimated)end dates | References |
|------------------------|--------------------|----------------------------|--------------------------------------|---------------------------|---------------------------------------------------------------|------------|
| Losmapimod             | p38 MAPK inhibitor | Not yet approved           | Reduce the acute exaggerated pro-inflammatory responses | NCT04511819 (Phase 3)    | Phase 3/NCT04511819/active, not recruiting/August 28, 2020–June 2021 | (Clinical trial ID: NCT04511819, n.d.) |
| Tradipitant            | Neurokinin-1 (NK-1) antagonist | Eczema, pruritus, gastroparesis, chronic pruritus, and atopic dermatitis | NK-1 antagonist involved in neuroinflammatory processes | NCT04326426 (Phase 3)    | Phase 3/NCT04326426/enrolling by invitation/April 13, 2020–August 1, 2020 | (Clinical trial ID: NCT04326426, n.d.) |
| Ifenprodil (NP-120)   | Noncompetitive N-methyl-d-aspartate (NMDA) receptor antagonist | Posttraumatic stress disorders | NDMA receptor-type subunit 2B antagonist and the subunit receptor mainly expressed on T cells and neutrophils | NCT04382924 (Phase 3)    | Phase 3/NCT04382924/active, not recruiting/August 5, 2020–January 2022 | (Clinical trial ID: NCT04382924, n.d.) |
| Prednisone             | Synthetic corticosteroid agent, upregulating natriuretic peptide receptor type A | Comparative study, immunosuppressive agents, inflammatory bowel disease, multiple sclerosis | Agonist of glucocorticosteroid, blocking inflammatory and immune responses. | NCT04534478 (Phase 4) NCT04344288 (Phase 2) | Phase 4/NCT04534478//not yet recruiting/September 7, 2020–May 2, 2021 | (Heman et al., 2020) |
| Hydrocortisone         | Human endogenous metabolite, steroid hormone or glucocorticoid secreted by the adrenal cortex | Coronary artery disease, healthy, septic shock, asthma | Agonist of glucocorticosteroid, blocking inflammatory and immune responses. | NCT04348305 (Phase 3) NCT02735707 (Phase 4) NCT02517489 (Phase 3) NCT04599959 (not applicable) NCT04563676 (not applicable) | Phase 4/NCT02735707/recruiting/April 11, 2016–December 2021 | (Copin et al., 2020; Petersen et al., 2020) |
| Dexamethasone          | Glucocorticoid receptor agonist | Cervical radiculopathy, cancer, inflammatory response, hip fracture, pain | Agonist of glucocorticosteroid, reducing CD11b, CD18, and CD62L | Approximately 31 clinical trials, some of the examples are: NCT04834375 (Phase 4) NCT04603729 (Phase 3) NCT04499313 (Phase 3) NCT04325061 (Phase 4) NCT04325061 (Phase 4) NCT04347980 (Phase 3) NCT04563494 (Phase 4) NCT03170882 (Phase 2) | Phase 4/NCT04834375/recruiting/March 19, 2021–March 19, 2022 | (Horby et al., 2021) |
| Drug name and structure | Original mechanism | FDA-approved indication(s) | Possible mechanism for anti-COVID-19 | Clinical trials ID (stage) | The highest anti-COVID-19 phase/ID/status/start-estimated end dates | References |
|-------------------------|--------------------|--------------------------|-------------------------------------|---------------------------|-------------------------------------------------------------|------------|
| Budesonide | Orally active glucocorticoid receptor agonist | Asthma | Glucocorticoid receptor agonist. Suppress the immune reaction locally in the respiratory system. | NCT04331470 (Phase 3) NCT04374474 (Phase 4) NCT04361474 (Phase 3) | Phase 4/NCT04374474/active, not recruiting/May 18, 2020–November 24, 2020 | (De León-Rendón et al., 2020) |
| Famotidine | Competitive histamine H2-receptor antagonist | Peptic ulcer, HIV infections, aspirin, dyspepsia, stomach ulcer, heartburn | Anti-inflammatory action | NCT04836806 (Phase 4) NCT04504240 (Phase 3) NCT04545008 (Phase 1) NCT04565392 (Phase 4) NCT04724720 (Phase 2) NCT04370262 (Phase 3) NCT04389567 (not applicable) | Phase 4/NCT04565392/not yet recruiting/May 1, 2021–November 1, 2021 | (Ennis & Tiligada, 2021) |
| Nitazoxanide | Antiprotozoal agent | Irritable bowel syndrome, hepatitis C, diabetes mellitus type 2 | Control excessive inflammatory immune responses | Approximately 24 clinical trials, some of the examples are: NCT04062446 (Phase 4) NCT04552483 (Phase 2) NCT04498936 (Phase 4) NCT04463264 (Phase 3) NCT04486313 (Phase 3) NCT04532931 (Phase 2) NCT04563208 (Phase 2) | Phase 4/NCT04498936/completed/July 15, 2020–October 30, 2020 | (Kelleni, 2020; Mahmoud et al., 2020; Pepprell et al., 2020) |
| Colchicine | Tubulin inhibitor and microtubule disrupting agent | Myocardial infarction, intercritical gout | Anti-inflammatory effects, an inhibitor of NLRP3 inflammasomes and mitigating interleukin activation. | Approximately 27 clinical trials, some of the examples are: NCT04818489 (Phase 4) NCT04392141 (Phase 2) NCT04416334 (Phase 3) NCT04472611 (Phase 3) NCT04322565 (Phase 2) NCT04724629 (Phase 3) NCT04492358 (Phase 3) | Phase 4/NCT04818489/recruiting/March 25, 2021–May 25, 2021 | (Deftereos et al., 2020; Nasiripour & Zamani, 2020) |
| Silymarin | p38 MAPK pathway inhibitor | Non-alcoholic fatty liver disease, metastatic colorectal cancer, hepatitis | Anti-inflammatory and anti-oxidant effects | NCT04394208 (Phase 3) NCT04816682 (Phase 4) | Phase 4/NCT04816682/recruiting/March 17, 2021–June 30, 2021 | (Clinical trial ID: NCT04394208, n.d.) |
| Methylprednisolone | | | | | | |
| Drug name and structure | Original mechanism | FDA-approved indication(s) | Possible mechanism for anti-COVID-19 | Clinical trials ID (stage) | The highest anti-COVID-19 phase/ID/status/start (estimated) end dates | References |
|-------------------------|-------------------|--------------------------|-------------------------------------|---------------------------|---------------------------------------------------------------|------------|
| Synthetic corticosteroid, anti-inflammatory and immunomodulating properties | COPD, purpura, schoenlein-henoch, postoperative pain, drug interaction potentiation, et al. | Anti-inflammatory, decreasing level of IL-6, ACE2 activation | Approximately 15 clinical trials, some of the examples are: NCT04499313 (Phase 3) NCT04485429 (Phase 3) NCT04603729 (Phase 3) NCT04826588 (Phase 3) NCT03708718 (Phase 2) NCT04780581 (Phase 4) NCT04765371 (Phase 3) | Phase 4/NCT04780581/recruiting/February 1, 2021–December 1, 2021 | (Edalatifard et al., 2020; Liu, Zheng, Huang, Shan, & Huang, 2020) |
| Enpatoran (M5049) | Dual TLR7/8 inhibitor | Systemic lupus erythematosus, Coronavirus Disease 2019 | Blocks the activation of toll-like receptor (TLR) 7 and TLR8, reduction in the inflammatory response | NCT04448756 (Phase 2) | Phase 2/NCT04448756/Active, not recruiting/June 26, 2020–August 22, 2021 | (Clinical trial ID: NCT04448756, n.d.) |
| EC-18 | Anti-inflammation | Stomatitis, chemotherapy-Induced neutropenia, febrile neutropenia | Anti-inflammatory, prevention of COVID-19 infection to severe pneumona or ARDS | NCT04500132 (Phase 2) NCT04569227 (Phase 2) | Phase 2/NCT04569227/recruiting/September 29, 2020–September 2021 | (Clinical trial ID: NCT04569227, n.d.) |
| APX-115 (Ewha-18,278) | pan NADPH oxidase (Nox) inhibitor | Healthy, diabetic nephropathies | NADPH-dependent generation of superoxide and secondary reactive oxygen species (ROS), ROS are often generated during virus infection, thus promoting apoptosis, lung injury, and inflammation/allergy. | NCT04880109 (Phase 2) | Phase 2/NCT04880109/not yet recruiting/May 10, 2021–February 2022 | (Clinical trial ID: NCT04880109, n.d.) |
| Drug name and structure | Original mechanism                                                                 | FDA-approved indication(s)                                                                 | Possible mechanism for anti-COVID-19                                                                 | Clinical trials ID (stage)                                      | The highest anti-COVID-19 phase/ID/status/start–(estimated) end dates                                                                                                                                                                                                                                                                                                                                 | References |
|------------------------|-----------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|
| Methotrexate           | Enzyme dihydrofolate reductase inhibitor, an immunosuppressant and antineoplastic agent | Rheumatoid arthritis, ophthalmopathy, thyroid-associated, psoriatic arthritis              | Immunomodulatory agent, preventing excessive immunereaction                                           | NCT04352465 (Phase 2) NCT04610567 (Phase 2)                     | Phase 2/NCT04610567 / recruiting/October 27, 2020–March 15, 2021                                                                                                                                                                                                                                                                                                                                                         | (Abuo-Rahma et al., 2020) |
| Leflunomide            | Dihydroorotate dehydrogenase inhibitor                                            | Rheumatoid arthritis, psoriatic arthritis, immunoglobulin G4 related sclerosing disease, juvenile idiopathic arthritis | Immunomodulatory agent, preventing excessive immunereaction                                           | NCT04532372 (Phase 2) NCT04361214 (Phase 1)                     | Phase 2/NCT04532372 / recruiting/January 7, 2021–September 18, 2022                                                                                                                                                                                                                                                                                                                                                      | (Abuo-Rahma et al., 2020) |
| Fingolimod             | Sphingosine 1-phosphate (S1P) antagonist, pak1 activator, a immunosuppressant     | Multiple sclerosis, relapsing–remitting                                                    | Immune modulator, S1P1 receptors antagonist                                                          | NCT04280588 (Phase 2)                                           | Phase 2/NCT04280588 / withdrawn (no participants enrolled)/ February 22, 2020–July 1, 2020                                                                                                                                                                                                                                                                                                                               | (Barzegar et al., 2020; Pelletier & Hafler, 2012) |
| Tamoxifen              | Selective estrogen receptor modulator (SERM), Hsp90 activator                    | Breast cancer, infertility, menorrhagia, endometrium                                       | Modulation of NK cells activity and reduce viral replication, through reducing PGE2 production         | NCT04389580 (Phase 2) NCT04568096 (Phase 2)                     | Phase 2/NCT04568096 / not yet recruiting/ November 2020–December 2020                                                                                                                                                                                                                                                                                                                                            | (Almosawey et al., 2020; Hamouda Elgarhy, 2020) |
| Isoprinosine           | Immunostimulant                                                                  | Immunostimulant                                                                           | Immunostimulant                                                                                     | NCT04360122 (Phase 3) NCT04383717 (Phase 3)                     | Phase 3/NCT04360122 / not yet recruiting/May 20, 2020–November 1, 2020                                                                                                                                                                                                                                                                                                                                           | (Clinical trial ID: NCT04360122, n.d.; Kumar et al., 2020) |
| IMU-838 (vidofludimus calcium) | Immunomodulatory agent, DHODH inhibitor, inhibiting IL-17 secreting               | Not yet approved                                                                           | Selective immunomodulatory effect against highly activated immune cells                            | NCT04516915 (Phase 2) NCT04379271 (Phase 3)                     | Phase 3/NCT04379271 / recruiting/June 11, 2020–September 2020                                                                                                                                                                                                                                                                                                                                            | (Clinical trial ID: NCT04379271, n.d.; Immunic Therapeutics website) |
| All-trans retinoic acid | Neutrophil elastase inhibitor, RAR nuclear receptor agonist                      | Acute promyelocytic leukemia                                                              | Enhance neutralizing antibodies                                                                      | NCT04396067 (Phase 2) NCT04568096 (Phase 2)                     | Phase 3/NCT04353180 / not yet recruiting/April 2021–June 2021                                                                                                                                                                                                                                                                                                                                            | (Clinical trial ID: NCT04396067, n.d.) |
| Drug name and structure | Original mechanism | FDA-approved indication(s) | Possible mechanism for anti-COVID-19 | Clinical trials ID (stage) | The highest anti-COVID-19 phase/ID/status/start-(estimated) end dates | References |
|------------------------|-------------------|---------------------------|-------------------------------------|---------------------------|---------------------------------------------------------------|------------|
| Melatonin              | Selective ATF-6 inhibitor | Parkinson’s disease, infertility, immediate dental implant, immediate dental implant, postoperative pain, anxiety, acute ischemic stroke | Modulate the immune response and neuroinflammation | Approximately 8 clinical trials, some of the examples are: NCT04474483 (Phase 2) NCT04470297 (Phase 2) NCT04568683 (Phase 2) NCT04353128 (Phase 3) NCT04409522 (not applicable) NCT0451748 (Phase 2) NCT04530539 (not applicable) | Phase 3/NCT04353128/recruiting/April 20, 2020–October 2020 | (Bahrampour Juybari et al., 2020) |
| Cyclosporinea (Synonyms: cyclosporine; Ciclosporin) | Immunosuppressant, inhibiting CD11a/CD18 adhesion | End-stage renal disease, renal function and chronic allograft vasculopathy, kidney transplantation, etc. | Immunomodulatory agent acting on T cells | NCT04540926 (Phase 2) NCT0412785 (Phase 1) NCT04492891 (Phase 2) NCT04392531 (Phase 4) NCT0451239 (not applicable) | Phase 4/NCT04392531/recruiting/April 16, 2020–March 2021 | (Rudnicka et al., 2020; Tian et al., 2020) |
| AZD1656                | Glucokinase activator | Type II diabetes | Activate the migration of T regulatory cells to sites of inflammation | NCT04516759 (Phase 2) | Phase 2/NCT04516759/completed/August 18, 2020–April 25, 2021 | (Clinical trial ID: NCT04516759, n.d.) |
| Drug name and structure | Original mechanism | FDA-approved indication(s) | Possible mechanism for anti-COVID-19 | Clinical trials ID (stage) | The highest anti-COVID-19 phase/ID/status/start–(estimated) end dates | References |
|------------------------|-------------------|---------------------------|-------------------------------------|---------------------------|---------------------------------------------------------------|------------|
| Ketamine | Antagonist of N-methyl D-aspartate receptor | Anesthesia, pain relief, sedation, and memory loss | Anesthesia, pain relief | NCT04365985 (Phase 2) | Phase 2/NCT04365985/recruiting/April 29, 2020–May 2021 | (Suri & Sindwani, 2020) |
| Aspirin | Non-selective and irreversible COX-1 and COX-2 inhibitor | Common cold, healthy, acute coronary syndrome, et al. | Interfering with normal platelet aggregation, COX-1 inhibitor | NCT04365309 (Phase 3) NCT043653840 (Phase 2) NCT04343001 (Phase 3) NCT04410328 (Phase 3) NCT04324463 (Phase 3) NCT04908895 (Phase 3) | Phase 3/NCT04410328/recruiting/October 21, 2020–March 15, 2021 | (Clinical trial ID: NCT04365309, n.d.; Bianconi et al., 2020) |
| Rivaroxaban | Selective and direct Factor Xa (FXa) inhibitor | Atherosclerosis, mitral valve stenosis, atrial fibrillation | Adequate antithrombotic therapy | NCT04504032 (Phase 2) NCT04508023 (Phase 3) NCT0441604 (Phase 3) NCT04324463 (Phase 3) | Phase 3/NCT04324463/recruiting/April 21, 2020–December 31, 2020 | (Di Tano et al., 2020) |
| Enoxaparin | Anticoagulant medication | Pulmonary embolism (PE), deep vein thrombosis (DVT) | Adequate antithrombotic therapy | Approximately 8 clinical trials, some of the examples are: NCT04427098 (Phase 2) NCT04366960 (Phase 3) NCT04400799 (Phase 3) NCT04540926 (Phase 2) NCT04492254 (Phase 3) NCT044608235 (Phase 3) NCT04640181 (Phase 2) | Phase 3/NCT04400799/recruiting/June 15, 2020–March 14, 2021 | (Drago et al., 2020) |
| Tranexamic acid | Antifibrinolytic agent, blocking lysine-binding sites of plasmin and elastase-derived plasminogen fragments | Prevent blood loss in surgical procedure | Antifibrinolytic agent, that competitively inhibits activation of plasminogen to plasmin, an enzyme that degrades fibrin clots. | NCT04338126 (Phase 2) NCT04550338 (Phase 3) NCT04338074 (Phase 2) | Phase 3/NCT04550338/not yet recruiting/December 1, 2020–December 31, 2022 | (Ogawa & Asakura, 2020) |
or phase I. There are 46 agents in approximately 294 trials in total (Figure 4). Among them, 10 agents aim at blocking virus-cell membrane fusion and entry, 11 small molecules inhibit viral replication, 16 small molecules address CSS, four small molecules modulate the innate immune system, four small molecules are used as anticoagulant therapy, and one small molecule is from the category of antioxidant supplement.

Of the drugs blocking virus-cell membrane fusion and entry, there are four agents (losartan, isotretinoin, lactoferrin, and propranolol) interacting with ACE2, one agent (linagliptin) inhibiting DPP4, two compounds (verapamil, chlorpromazine) targeting on ion channel, one agent (dapagliflozin) reducing the viral load, and two agents (nafamostat and bicalutamide) blocking TMPRSS2. Of the drugs targeting virus replication, there are two reverse transcriptase inhibitors (emtricitabine and tenofovir alafenamide), five RNA-targeting agents (remdesivir, ciclesonide, EIDD-2801, AT-527 and ribavirin), one phosphodiesterase inhibitor (dipyridamole), one Impα/β1-mediated nuclear import inhibitor (ivermectin), one Mpro inhibitor (rosuvastatin) and one 3CLpro inhibitor (PF-07321332). In the category of the drugs addressing CSS, there are three JAK inhibitors (ruxolitinib, baricitinib, and niclosamide), five interleukin modulators (levamisole, opaganib, anakinra, atorvastatin, and PTC299), two modulators targeting inflammatory cytokines release (amiodarone, and VERU-111), one inflammatory inhibitor (escin), one tyrosine kinase inhibitor (imatinib), one cysteine leukotriene (cysLT) receptor antagonist (montelukast), one p38 MAPK pathway inhibitors (loasmapimod), one neurokinin-1 (NK-1) antagonist (tradipitant), and one N-methyl-d-aspartate (NMDA) receptor antagonist (ifenprodil). There is only one agent (N-acetylcysteine) belonging to antioxidant supplement sub-class. Dipyridamole does not inhibit the SARS-CoV-2 main protease. Its antiviral activity might involve other mechanisms (Ma & Wang, 2021).

### 3.3 Phase IV clinical candidates

Phase IV clinical trial is conducted by the applicant after the new drug has already been approved by FDA. The main objective in this phase is to assess the long-term benefits and risks of using the drug in general population groups or in special population groups. In category, there are 34 agents in approximately 386 trials (Figure 4). Among them, 10 agents aim at blocking virus-cell membrane fusion and entry, 7 small molecules inhibit viral replication, 11 small molecules address CSS, 1 small molecule modulates immune system. In addition, there are currently 2 agents used as anticoagulant therapy and 3 agents identified as antioxidant supplements.

Of those drugs blocking virus-cell membrane fusion and entry, three agents are TMPRSS2 inhibitors (bromhexine, camostat, and spironolactone), three agents (valsrartan, arbidol and canrenoate potassium) interact with ACE2. One agent (azithromycin) interferes with S protein/CD147 interaction, one agent (tetrindrine) inhibits voltage-gated Ca^{2+} current (ICa) and Ca^{2+}-activated K+ current, one agent...
| Drug name and structure | Original mechanism | FDA-approved indication(s) | Possible mechanism for anti-COVID-19 | Clinical trials ID (stage) | The highest anti-COVID-19 phase/ID/status/start (estimated) end dates | References |
|-------------------------|------------------|-----------------------------|-------------------------------------|---------------------------|---------------------------------------------------------------|------------|
| N-acetylcysteine        | ROS inhibitor, mucolytic agent reducing thickness of mucus | Gastric mucosal lesion, polycystic ovary syndrome, etc. | Antioxidant precursor to glutathione (γ-glutamylcysteinylglycine), mucolytic agent | NCT04374461 (Phase 2) NCT04792021 (Phase 3) NCT04545008 (Phase 1) NCT04458298 (Phase 2) NCT04419025 (Phase 2) NCT04703036 (Phase 1) NCT04755972 (not applicable) | Phase 3/NCT04792021/ recruiting/March 9, 2021–June 2021 | (Andreou et al., 2020; Poe & Com, 2020) |
| Vitamin C (ascorbic acid) | Effective reducing agent and donor antioxidant | Scurvy, upper respiratory tract infections, reduces the risk of lung cancer | Upregulating phagocytes and lymphocytes activity, modulating immune system | Approximately 24 clinical trials, some of the examples are: NCT04401150 (Phase 3) NCT04468139 (Phase 4) NCT04363216 (Phase 2) NCT04264533 (Phase 2) NCT02735707 (Phase 4) NCT04780061 (Phase 3) NCT04828538 (not applicable) | Phase 4/NCT02735707/ recruiting/11, 2016–December 2021 | (Baladia et al., 2020) |
| Vitamin D3 (Cholecalciferol) | Inducing cell differentiation and preventing the proliferation of cancer cells | Epilepsy, healthy, vitamin D deficiency, osteoporosis | Protect respiratory infections | Approximately 14 clinical trials, some of the examples are: NCT04344041 (Phase 3) NCT04536298 (Phase 3) NCT04411446 (Phase 4) NCT04482673 (Phase 4) NCT04407286 (Phase 1) NCT04386500 (Phase 3) NCT04395768 (Phase 2) | Phase 4/NCT04482673/ recruiting/July 31, 2020–December 31, 2021 | (Weir et al., 2020) |
| Quercetin               | Stimulator of recombinant SIRT1, PI3K inhibitor | Menopause related conditions, mountain sickness, flushing | Prophylactic, antioxidant | NCT04853199 (early Phase 1) NCT04578158 (Phase 2) NCT04468139 (Phase 4) NCT04536090 (Phase 2) NCT04377889 (not applicable) | Phase 4/NCT04468139/ recruiting/June 20, 2020–July 20, 2020 | (Diniz et al., 2020) |
(doxycycline) inhibits the E2 envelope glycoprotein involved in virus entry, and one binder of surface proteins of enveloped viruses (povidone-iodine). Of those drugs targeting virus replication, two agents (ritonavir and lopinavir) inhibit the coronaviral 3CLpro protease, one compound (oseltamivir) blocks virus-release, three agents (favipiravir, ledipasvir, and sofosbuvir) target RdRp, and 1 agent (darunavir) inhibits HIV protease. Of those drugs addressing CSS, there are four glucocorticosteroi agonists (prednisone, hydrocortisone, dexamethasone, and budesonide), one competitive histamine H2-receptor antagonist (famotidine), 1 antiproteozol agent (nitazoxanide), four interleukin modulators (colchicine, methylprednisolone, deferoxamine and cefditoren), one mTOR inhibitor (sirolimus), and one p38 MAPK pathway inhibitor (silymarin). In addition, there is 1 immuno suppressive drug (cyclosporine A) which could modulate the immune system. Apixaban and rivaroxaban belong to anticoagulant therapy, vitamin C, vitamin D3, and quercetin are used as antioxidant supplements.

4 | CONCLUSIONS AND OUTLOOK

At present, several COVID-19 vaccines have been approved for clinical use in many countries worldwide. The vaccine approach aims at the preventive management, which will increase antibody level against the virus and reduce the probability for viral infection in a certain extent. However, the vaccine approach is not suitable for those people already infected with the virus. As SARS-CoV-2 continues to worsen global health conditions and economic situations, the number of people infected with this virus continues climbing. Therefore, seeking effective medicines to treat COVID-19 is urgently needed. This review gathers all small molecules currently in active clinical trials, categorizes them into six sub-classes, and analyzes possible therapeutic treatments and their underlying mechanisms against COVID-19. Among all of the clinical trials, the antioxidant supplement sub-class accounts for the smallest percentile, while addressing CSS sub-class accounts for the largest percentile. Blocking virus-cell membrane fusion/entry and inhibiting virus replication are two sub-classes next to addressing CSS sub-class, and together these two sub-classes account for 42% of all clinical agents. The agents from the above two sub-classes are all belonged to repurposing drugs. Some preliminary results from the studies using repurposing antiviral drugs in clinic have demonstrated the efficacy in blocking virus-cell membrane fusion and entry or inhibiting virus replication. In addition, given the hyperinflammatory response mediated by addressing CSS agents or modulating immune system agents are expected to work in preventing body deterioration. Finally, Anticoagulant therapy and antioxidant supplement are also playing important roles in combating COVID-19. However, their effectiveness, safety/side-effects remain to be watched. In summary, repurposing antiviral and anticancer drugs for treatment of COVID-19 show promising. The races of small molecules for the treatment of COVID-19 are intense, and is likely to show some promise in the future.

ACKNOWLEDGMENTS

This work was funded by the National Natural Science Foundation of China (82073686, 81730108, 81973635, and 81803340), Hangzhou “115” overseas intelligence program (2020C001), Hangzhou Normal University startup fund (4125C5021920419), Hangzhou Normal University, School of Medicine Teaching Reform Fund (4125b30100112).

CONFLICT OF INTEREST

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

DATA AVAILABILITY STATEMENT

Data sharing is not applicable to this article as no new data were created or analyzed in this study.

ORCID

Suwen Hu https://orcid.org/0000-0002-3991-645X
Songwei Jiang https://orcid.org/0000-0003-2698-7125
Xiang Qi https://orcid.org/0000-0002-6408-2696
Renren Bai https://orcid.org/0000-0002-3511-5794
Xiang-Yang Ye https://orcid.org/0000-0003-7379-0930
Tian Xie https://orcid.org/0000-0001-7066-1443

REFERENCES

Abuo-Rahma, G. E.-D. A., Mohamed, M. F. A., Ibrahim, T. S., Shoman, M. E., Samir, E., & Abd El-Baky, R. M. (2020). Potential repurposed SARS-CoV-2 (COVID-19) infection drugs. RSC Advances, 10(45), 26895–26916. https://doi.org/10.1039/D0RA05821A
Akram, J., Azhar, S., Shahzad, M., Latif, W., & Khan, K. S. (2020). Pakistan randomized and observational trial to evaluate coronavirus treatment (PROTect) of Hydroxychloroquine, Oseltamivir and azithromycin to treat newly diagnosed patients with COVID-19 infection who have no comorbidities like diabetes mellitus: A structured summary of a study protocol for a randomized controlled trial. Trials, 21(1), 702.
Al-Horani, R. A. (2020). Potential therapeutic roles for direct factor Xa inhibitors in coronavirus infections. American Journal of Cardiovascular Drugs, 20(6), 525–533. https://doi.org/10.1007/s40256-020-00438-6
Almosawey, H., Al-Khikani, F., Hameed, R. M., Abdulllah, Y. J., & Alasadi, A. A. (2020). Tamoxifen from chemotherapy to antiviral drug: Possible activity against COVID19. Biomedical and Biotechnology Research Journal (BBRJ), 4(2), 108–116.
Amat-Santos, I. J., Santos-Martinez, S., Lopez-Otero, D., Nombela-Franco, L., Gutiérrez-Ibanes, E., Del Valle, R., ... San Román, J. A. (2020). Ramipril in high-risk patients with COVID-19. Journal of the American College of Cardiology, 76(3), 268–276. https://doi.org/10.1016/j.jacc.2020.05.040
Andreou, A., Trantza, S., Filippou, D., Sipsas, N., & Tsiodras, S. (2020). COVID-19: The potential role of copper and N-acetylcyesteine (NAC) in a combination of candidate antiviral treatments against SARS-CoV-2. In Vivo, 34(3 Suppl), 1567–1588. https://doi.org/10.21873/invivo.11946
Assimakopoulos, S. F., Seintis, F., & Marangos, M. (2020). Pentoxifylline and complicated COVID-19: A pathophysiologically based treatment proposal. Medical Hypotheses, 143, 109926. https://doi.org/10.1016/j.mehy.2020.109926
Ayerdi, O., Puerta, T., Clavo, P., Vera, M., Ballesteros, J., Fuentes, M. E., ... Del Romero, J. (2020). Preventive efficacy of Tenofovir/Emtricitabine against severe acute respiratory syndrome coronavirus 2 among pre-
Mehta, P., McAuley, D. F., Brown, M., Sanchez, E., Tattersall, R. S., & Manson, J. J. (2020). COVID-19: Consider cytokine storm syndromes and immunosuppression. Lancet, 395(10229), 1033–1034.

Merck Company website. Retrieved from https://www.businesswire.com/news/home/20210111005110/en/. Accessed October 11, 2021.

Mercorelli, B., Palú, G., & Lorenzini, A. (2018). Drug repurposing for viral infectious diseases: How far are we? Trends in Microbiology, 26(10), 865–876. https://doi.org/10.1016/j.tim.2018.04.004

Messerli, F. H., Sions, G. C. M., & Rokhaj, E. (2020). COVID-19 and renin angiotensin blockers: Current evidence and recommendations. Circulation, 141(25), 2042–2044. https://doi.org/10.1161/circulationaha.120.047022

Mevada, V., Duhagara, P., Gandhi, H., Vaghamsi, N., & Patel, R. (2020). Drug repurposing of approved drugs Elbasvir, Ledipasvir, Paritaprevir, Velpatasvir, Anafenrine and Ergotamine for Combating COVID19.

Millán-Oñate, J., Millan, W., Mendoza, L. A., Sánchez, C. G., Fernandez-Sanchez, H., Bonilla-Aldana, D. K., & Rodríguez-Morales, A. J. (2020). Successful recovery of COVID-19 pneumonia in a patient from Colombia after receiving chloroquine and clari-thromycin. Annals of Clinical Microbiology and Antimicrobials, 19(1), 16. https://doi.org/10.1186/s12941-020-00358-y

Monpara, J. D., Sodha, S. J., & Gupta, P. K. (2020). COVID-19 associated complications and potential therapeutic targets. European Journal of Pharmacology, 886, 173548. https://doi.org/10.1016/j.ejphar.2020.173548

Nasiripour, S., & Zamani, F. (2020). Can colchicine as an old anti-inflammatory agent be effective in COVID-19? Journal of Clinical Pharmacology, 60(7), 828–829. https://doi.org/10.1002/jcp.1645

Neubauer, A., Wiesmann, T., Vogelmeier, C. F., Mack, E., Skevaki, C., Ojha, P. K., Kar, S., Krishna, J. G., Roy K., & Leszczynski J. (2021). Theranews press from WHO website WHO discontinues hydroxychloroquine and lopinavir/ritonavir treatment arms for COVID-19. Retrieved from https://doi.org/10.10111/odi.13378

Pelletier, D., & Hafler, D. A. (2012). Fingolimod for multiple sclerosis. The New England Journal of Medicine, 366(4), 339–347. https://doi.org/10.1056/NEJMc1101691

Pepperrell, T., Pilkington, O., Owen, A., Wang, J., & Hill, A. M. (2020). Review of safety and minimum pricing of nitazoxanide for potential treatment of COVID-19. Journal of Virus Eradication, 6(2), 52–60. https://doi.org/10.21055-j2055-6640(20)30017-0

Petersen, M. W., Meyhoff, T. S., Granholm, A., Hjortsø, C. J. S., Helleberg, M., Kjaer, M. N., … Rasmussen, B. S. (2020). Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia (COVID STEROID) trial-protocol and statistical analysis plan. Acta Anaesthesiologica Scandinavica, 64(9), 1365–1375. https://doi.org/10.1111/aas.13673

Pharmacology, 688. https://doi.org/10.1016/j.drudis.2020.01.015

Pindiprolu, S., & Pindiprolu, S. H. (2020). Plausible mechanisms of Niclosamide as an antiviral agent against COVID-19. Medical Hypotheses, 140, 109765. https://doi.org/10.1016/j.mehy.2020.109765

Poe, F. L., & Conn, J. (2020). N-Acetylcysteine: A potential therapeutic agent for SARS-CoV-2. Medical Hypotheses, 143, 109862.

Poissy, J., Goutay, J., Caplan, M., Parmentier, E., Dubucq, T., Lassalle, F., … Susen, S. (2020). Pulmonary embolism in patients with COVID-19: Awareness of an increased prevalence. Circulation, 142(2), 184–186.

PubChem National Library of Medicine. Retrieved from https://pubchem.ncbi.nlm.nih.gov/compound/eidd-2801. Accessed August 15, 2021.

Rashid, H. U., Ahmad, N., Abdalla, M., Khan, K. A., Martines, M. A. U., & Shabana, S. (2022). Molecular docking and dynamic simulations of Cefixime, Etoposide and Nebrodoside against the pathogenic proteins of SARS-CoV-2. Journal of Molecular Structure, 1247, 131296. https://doi.org/10.1016/j.molstruc.2021.131296

Roschewski, M., Tieu, K. V., Wang, Y., Bakovic, A., Alem, F., Bhalla, N., … Lionakis, M. S. (2020). Maraviroc inhibits SARS-CoV-2 multiplication and s-protein mediated cell fusion in cell culture. bioRxiv. dohttps://doi.org/10.1101/2020.08.12.244389.

Rudnicka, L., Glowacka, P., Goldust, M., Sikora, M., Sar-Pomian, M., … Topp, M., Rudnicka, A. (2020). Hydroxychloroquine and lopinavir/ritonavir treatment arms for COVID-19. Retrieved from https://www.who.int/news/item/04-07-2020-who-discontinues-hydroxychloroquine-and-lopinavir-ritonavir-treatment-arms-for-covid-19. Accessed August 15, 2021.

Rohmi, H., Ahmad, N., Abdalla, M., Khan, K. A., Martines, M. A. U., & Shabana, S. (2022). Molecular docking and dynamic simulations of Cefixime, Etoposide and Nebrodoside against the pathogenic proteins of SARS-CoV-2. Journal of Molecular Structure, 1247, 131296. https://doi.org/10.1016/j.molstruc.2021.131296

Risner, K. H., Tieu, K. V., Wang, Y., Bakovic, A., Alem, F., Bhalla, N., … Lionakis, M. S. (2020). Maraviroc inhibits SARS-CoV-2 multiplication and s-protein mediated cell fusion in cell culture. bioRxiv. dohttps://doi.org/10.1101/2020.08.12.244389.

Roop, M., Ghasemi, V., & Tavakoli, Z. (2020). Immune responses and pathogenesis of SARS-CoV-2 during an outbreak in Iran: Comparison with SARS and MERS. Reviews in Medical Virology, 30(3), e2107. https://doi.org/10.1002/rmv.2107.

Roschewski, M., Lionakis, M. S., Sharman, J. P., Roswarski, J., Goy, A., Monticelli, M. A., … Wilson, A. (2020). Inhibition of Bruton tyrosine kinase in patients with severe COVID-19. Science Immunology, 5(48), eabd0110. https://doi.org/10.1126/sciimmunol.abd0110

Rudnicka, L., Glowacka, P., Goldust, M., Sikora, M., Sar-Pomian, M., Rakowska, A., … Olszewska, M. (2020). Cyclosporine therapy during the COVID-19 pandemic. Journal of the American Academy of Dermatology, 83(2), e151–e152. https://doi.org/10.1016/j.jaad.2020.04.153

Sachdeva, C., Wadhwa, A., Kumari, A., Hussain, F., Jha, P., & Kaushik, N. K. (2020). In silico potential of approved antimalarial drugs for repurposing against COVID-19. OMICS, 24(10), 568–580. https://doi.org/10.1089/omi.2020.0071

Saeedi-Boroujeni, A., & Mahmoudian-Sani, M. R. (2021). Anti-inflammatory potential of Quercetin in COVID-19 treatment. Journal of Inflammation, 18(1), 3. https://doi.org/10.1186/s12950-021-00268-6

Sahin, A. R., Erdogan, A., Agaoglu, P. M., Dineri, Y., Cakirci, A. Y., Senel, M. E., … Tasdogan, A. M. (2020). 2019 novel coronavirus.
(COVID-19) outbreak: A review of the current literature. *Eurasian Journal of Medicine and Oncology*, 4(1), 1–7. https://doi.org/10.14744/ ejmo.2020.12220

Sahoo, B. M., Ravi Kumar, B. V. V., Sruti, J., Mahapatra, M. K., Banik, B. K., & Borah, P. (2021). Drug repurposing strategy (DRS): Emerging approach to identify potential therapeutics for treatment of novel coronavirus infection. *Frontiers in Molecular Biosciences*, 8, 628144. https://doi.org/10.3389/fmolb.2021.628144

Sanchis-Gomar, F., Lavie, C. J., Morin, D. P., Perez-Quilis, C., Laukkonen, J. A., & Perez, M. V. (2020). Amiodarone in the COVID-19 era: Treatment for symptomatic patients only, or drug to prevent infection? *American Journal of Cardiovascular Drugs*, 20(5), 413–418. https://doi.org/10.1007/s40256-020-00429-7

Sanders, J. M., Monogue, M. L., Jodlowski, T. Z., & Cutrell, J. B. (2020). Pharmacologic treatments for coronavirus disease 2019 (COVID-19): A review. *JAMA*, 323(18), 1824–1836. https://doi.org/10.1001/jama.2020.6019

Sayad, B., Sodhani, M., & Khodarahimi, R. (2020). Sofosbuvir as repurposed antiviral drug against COVID-19: Why were we convinced to evaluate the drug in a registered/approved clinical trial? *Archives of Medical Research*, 51(6), 577–581. https://doi.org/10.1016/j.arcmed.2020.04.018

Self, W. H., Semler, M. W., Leither, L. M., Casey, J. D., Angus, D. C., Brower, R. G., ... Diercks, D. (2020). Effect of Hydroxychloroquine on clinical status at 14 days in hospitalized patients with COVID-19: A randomized clinical trial. *JAMA*, 324(21), 2165–2176. https://doi.org/10.1001/jama.2020.22240

Shamsi, A., Mohammad, T., AlAjmi, M. F., Hussain, A., Shamsi, A., Mohammad, T., AlAjmi, M. F., Hussain, A., Sheahan, T. P., Sims, A. C., Zhou, S., Graham, R. L., Pruijssers, A. J., cjb.200049. https://doi.org/10.1007/s41581-020-0279-4

Suri, A., & Sindwani, G. (2020). Ketamine use in the COVID-19 era: Be cautious! *Korean Journal of Anesthesiology*, 73(6), 568–569. https://doi.org/10.4097/kja.20318

Tan, W. Y. T., Young, B. E., Lye, D. C., Chew, D. E. K., & Dalan, R. (2020). Statin use is associated with lower disease severity in COVID-19 infection. *Scientific Reports*, 10(1), 17458. https://doi.org/10.1038/s41598-020-74492-0

Tang, N. L., Chan, P. K., Wong, C. K., To, K. F., Wu, A. K., Sung, Y. M., ... Lam, C. W. (2005). Early enhanced expression of interferon-inducible protein-10 (CXCL-10) and other chemokines predicts adverse outcome in severe acute respiratory syndrome. *Clinical Chemistry*, 51(12), 2333–2340. https://doi.org/10.1373/chinchem.2005.054460

Tay, M. Z., Poh, C. M., Renia, L., MacAry, P. A., & Ng, L. F. P. (2020). The trinity of COVID-19: Immunity, inflammation and intervention. *Nature Reviews. Immunology*, 20(6), 363–374. https://doi.org/10.1038/s41587-020-0311-8

Tian, L., Liu, W., & Sun, L. (2020). Role of cyclophilin a during coronavirus replication and the antiviral activities of its inhibitors. *Sheng Wu Ji Chuan Xue Bao*, 36(4), 605–611. https://doi.org/10.13345/j.cjb.200049

Tobinick, E. L. (2009). The value of drug repositioning in the current pharmaceutical market. *Drug News & Perspectives*, 22(2), 119–125.

Tong, S., Su, Y., Yu, Y., Wu, C., Chen, J., Wang, S., & Jiang, J. (2020). Ribavirin therapy for severe COVID-19: A retrospective cohort study. *International Journal of Antimicrobial Agents*, 56(3), 10614. https://doi.org/10.1016/j.ijantimicag.2020.10614

Tong, X., Smith, J., Bukreyeva, N., Koma, T., Manning, J. T., Kalker, R., ... Paesels, S. (2018). Merimepodib, an IMPDH inhibitor, suppresses replication of Zika virus and other emerging viral pathogens. *Antiviral Research*, 149, 34–40. https://doi.org/10.1016/j.antiviral.2017.11.004

Treon, S. P., Castillo, J. J., Skarbnik, A. P., Soumerai, J. D., Ghobrial, I. M., Guerrera, M. L., ... Yang, G. (2020). The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients. *Blood*, 135(21), 1912–1915. https://doi.org/10.1182/blood.2020006288

Uddin, M. H., Zonder, J. A., & Azmi, A. S. (2020). Exportin 1 inhibition as antiviral therapy. *Drug Discovery Today*, 25(10), 1775–1781.

Ullrich, H., & Pillat, M. M. (2020). CD147 as a target for COVID-19 treatment: Suggested effects of azithromycin and stem cell engagement. *Stem Cell Reviews and Reports*, 16(3), 434–440. https://doi.org/10.1007/s12015-020-09976-7

Uyaroglu, O. A., Güven, G. S., & Güllü, İ. (2020). Can Levamisole be used in the treatment of COVID-19 patients presenting with diarrhea? *Journal of Infection in Developing Countries*, 14(8), 844–846. https://doi.org/10.3855/jidc.13101

Valencia, D. N. (2020). Brief review on COVID-19: The 2020 pandemic caused by SARS-CoV-2. *Cureus*, 12(3), e7386. https://doi.org/10.7759/cureus.7386

Vandyck, K., & Deval, J. (2021). Considerations for the discovery and development of 3-chymotrypsin-like cysteine protease inhibitors targeting SARS-CoV-2 infection. *Current Opinion in Virology*, 49, 36–40. https://doi.org/10.1016/j.covi.2021.04.006

Vasanthakumar, N. (2020). Beta-adrenergic blockers as a potential treatment for COVID-19 patients presenting with diarrhea? *Cureus*, 4(1), 630. https://doi.org/10.1038/s41581-020-0279-4

Vitiello, A., La Porta, R., & Ferrara, F. (2020). Sacubitril, valsartan and SARS-CoV-2. *BMJ Evidence-Based Medicine*, 26, 205. https://doi.org/10.1136/bmjebm-2020-111497

Walls, A. C., Park, Y. J., Tortorici, M. A., Wall, A., McGuire, A. T., & Veesler, D. (2020). Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. *Cell*, 181(2), 281–292.e286. https://doi.org/10.1016/j.cell.2020.02.058
Wan, S., Yi, Q., Fan, S., Lv, J., Zhang, X., Guo, L., ... Chen, Y. (2020). Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP). medRxiv. https://doi.org/10.1101/2020.02.10.20021832

Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., ... Peng, Z. (2020). Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA, 323(11), 1061–1069. https://doi.org/10.1001/jama.2020.1585

Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., ... Xiao, G. (2020). Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Research, 30(3), 269–271. https://doi.org/10.1038/s41422-020-0282-0

Wang, W., McLeod, H. L., & Cassidy, J. (2003). Disulfiram-mediated inhibition of NF-kappaB activity enhances cytotoxicity of 5-fluorouracil in human colorectal cancer cell lines. International Journal of Cancer, 104(4), 504–511. https://doi.org/10.1002/ijc.10972

Weir, E. K., Thenapann, T., Bhargava, M., & Chen, Y. (2020). Does vitamin D deficiency increase the severity of COVID-19? Clinical Medicine (London, England), 20(4), e107-e108. https://doi.org/10.7861/clinmed.2020-0301

Whitley, R. J. (2007). The role of oseltamivir in the treatment and prevention of influenza in children. Expert Opinion on Drug Metabolism & Toxicology, 3(5), 755–767. https://doi.org/10.1517/17425255.3.5.755

World Health Organization website. Coronavirus (COVID-19) data. Retrieved from www.who.int/data#reports. Accessed August 15, 2021.

Wu, R., Wang, L., Kuo, H.-C. D., Shannar, A., Peter, R., Chou, P. J., ... Kong, A.-N. (2020). An update on current therapeutic drugs treating COVID-19. Current Pharmacology Reports, 6(3), 56–70. https://doi.org/10.1007/s40495-020-00216-7

Xu, J., Shi, P. Y., Li, H., & Zhou, J. (2020). Broad Spectrum antiviral agent Niclosamide and its therapeutic potential. ACS Infectious Diseases, 6(5), 909–915. https://doi.org/10.1021/acs.infectiondis.0c00052

Xu, Z., Shi, L., Wang, Y., Zhang, J., Huang, L., Zhang, C., ... Wang, F. S. (2020). Pathological findings of COVID-19 associated with acute respiratory distress syndrome. The Lancet Respiratory Medicine, 8(4), 420–422. https://doi.org/10.1016/s2213-2600(20)30076-x

Yan, V. C., & Muller, F. L. (2020). Advantages of the parent nucleoside GS-441524 over Remdesivir for Covid-19 treatment. ACS Medicinal Chemistry Letters, 11(7), 1361-1366. https://doi.org/10.1021/acsmedchemlett.0c00316

Yang, N., & Shen, H. M. (2020). Targeting the Endocytic pathway and autophagy process as a novel therapeutic strategy in COVID-19. International Journal of Biological Sciences, 16(10), 1724–1731. https://doi.org/10.7150/ijbs.45498

Ye, Q., Wang, B., & Mao, J. (2020). The pathogenesis and treatment of the “cytokine storm” in COVID-19. The Journal of Infection, 80(6), 607–613. https://doi.org/10.1016/j.jinf.2020.03.037

Yousefi, J., Mashouri, L., Okpechi, S. C., Alahari, N., & Alahari, S. K. (2021). Repurposing existing drugs for the treatment of COVID-19/SARS-CoV-2 infection: A review describing drug mechanisms of action. Biochemical Pharmacology, 183, 114296.

Zeidler, A., & Karpinski, T. M. (2020). SARS-CoV, MERS-CoV, SARS-CoV-2 comparison of three emerging coronaviruses. Jundishapur Journal of Microbiology, 13(6), e103744.

Zeng, X., Song, X., Ma, T., Pan, X., Zhou, Y., Hou, Y., ... Cheng, F. (2020). Repurpose open data to discover therapeutics for COVID-19 using deep learning. Journal of Proteome Research, 19(11), 4624–4636. https://doi.org/10.1021/acs.jproteome.0c00316

Zhang, H., Penninger, J. M., Li, Y., Zhong, N., & Slutsky, A. S. (2020). Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: Molecular mechanisms and potential therapeutic target. Intensive Care Medicine, 46(4), 586–590. https://doi.org/10.1007/s00134-020-05985-9

Zhang, L., Lin, D., Sun, X., Curth, U., Drosten, C., Sauererling, L., ... Hilgenfeld, R. (2020). Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors. Science, 368(6489), 409–412. https://doi.org/10.1126/science.abb3405

Zhou, Y., Fu, B., Zheng, X., Wang, D., Zhao, C., Qi, Y., ... Wei, H. (2020). Aberrant pathogenic GM-CSF+ T cells and inflammatory CD14+ CD16+ monocytes in severe pulmonary syndrome patients of a new coronavirus. National Science Review, 7(6), 998–1002. http://dx.doi.org/10.1093/nsr/nwaa041

Zhou, Y., Hou, Y., Shen, J., Huang, Y., Martin, W., & Cheng, F. (2020). Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2. Cell Discovery, 6, 14.

Zhu, Y., Li, J., & Pang, Z. (2021). Recent insights for the emerging COVID-19: Drug discovery, therapeutic options and vaccine development. Asian Journal of Pharmaceutical Sciences, 16(1), 4–23. https://doi.org/10.1016/j.ajps.2020.06.001

How to cite this article: Hu, S., Jiang, S., Qi, X., Bai, R., Ye, X.-Y., & Xie, T. (2022). Races of small molecule clinical trials for the treatment of COVID-19: An up-to-date comprehensive review. Drug Development Research, 83(1), 16–54. https://doi.org/10.1002/ddr.21895